<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69601</article-id><article-id pub-id-type="doi">10.7554/eLife.69601</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Hsp40s play complementary roles in the prevention of tau amyloid formation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-236784"><name><surname>Irwin</surname><given-names>Rose</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1147-4944</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-236783"><name><surname>Faust</surname><given-names>Ofrah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0105-5922</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236782"><name><surname>Petrovic</surname><given-names>Ivana</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4461-7603</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa3">#</xref></contrib><contrib contrib-type="author" id="author-92634"><name><surname>Wolf</surname><given-names>Sharon Grayer</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5337-5063</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198896"><name><surname>Hofmann</surname><given-names>Hagen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-87289"><name><surname>Rosenzweig</surname><given-names>Rina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4019-5135</contrib-id><email>rina.rosenzweig@weizmann.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Chemical and Structural Biology, Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff><aff id="aff2"><label>2</label><institution>Department of Chemical Research Support, Weizmann Institute of Science</institution><addr-line><named-content content-type="city">Rehovot</named-content></addr-line><country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Andreotti</surname><given-names>Amy</given-names></name><role>Reviewing Editor</role><aff><institution>Iowa State University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>Program in Molecular Medicine, Hospital for Sick Children, Toronto, Canada</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Biochemistry, University of Toronto, Toronto, Canada</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Biozentrum, University of Basel, Basel, Switzerland</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e69601</elocation-id><history><date date-type="received" iso-8601-date="2021-04-20"><day>20</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-08"><day>08</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-04-11"><day>11</day><month>04</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.04.11.439324"/></event></pub-history><permissions><copyright-statement>© 2021, Irwin et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Irwin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69601-v2.pdf"/><abstract><p>The microtubule-associated protein, tau, is the major subunit of neurofibrillary tangles associated with neurodegenerative conditions, such as Alzheimer's disease. In the cell, however, tau aggregation can be prevented by a class of proteins known as molecular chaperones. While numerous chaperones are known to interact with tau, though, little is known regarding the mechanisms by which these prevent tau aggregation. Here, we describe the effects of ATP-independent Hsp40 chaperones, DNAJA2 and DNAJB1, on tau amyloid-fiber formation and compare these to the small heat shock protein HSPB1. We find that the chaperones play complementary roles, with each preventing tau aggregation differently and interacting with distinct sets of tau species. Whereas HSPB1 only binds tau monomers, DNAJB1 and DNAJA2 recognize aggregation-prone conformers and even mature fibers. In addition, we find that both Hsp40s bind tau seeds and fibers via their C-terminal domain II (CTDII), with DNAJA2 being further capable of recognizing tau monomers by a second, distinct site in CTDI. These results lay out the mechanisms by which the diverse members of the Hsp40 family counteract the formation and propagation of toxic tau aggregates and highlight the fact that chaperones from different families/classes play distinct, yet complementary roles in preventing pathological protein aggregation.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Several neurological conditions, such as Alzheimer’s and Parkinson’s disease, are characterized by the build-up of protein clumps known as aggregates. In the case of Alzheimer’s disease, a key protein, called tau, aggregates to form fibers that are harmful to neuronal cells in the brain. One of the ways our cells can prevent this from occurring is through the action of proteins known as molecular chaperones, which can bind to tau proteins and prevent them from sticking together.</p><p>Tau can take on many forms. For example, a single tau protein on its own, known as a monomer, is unstructured. In patients with Alzheimer’s, these monomers join together into small clusters, known as seeds, that rapidly aggregate and accumulate into rigid, structured fibers. One chaperone, HSPB1, is known to bind to tau monomers and prevent them from being incorporated into fibers. Recently, another group of chaperones, called J-domain proteins, was also found to interact with tau. However, it was unclear how these chaperones prevent aggregation and whether they bind to tau in a similar manner as HSPB1.</p><p>To help answer this question, Irwin, Faust et al. studied the effect of two J-domain proteins, as well as the chaperone HSBP1, on tau aggregation. This revealed that, unlike HSBP1, the two J-domain proteins can bind to multiple forms of tau, including when it has already aggregated in to seeds and fibers. This suggests that these chaperones can stop the accumulation of fibers at several different stages of the aggregation process. Further experiments examining which sections of the J-domain proteins bind to tau, showed that both attach to fibers via the same region. However, the two J-domain proteins are not identical in their interaction with tau. While one of them uses a distinct region to bind to tau monomers, the other does not bind to single tau proteins at all.</p><p>These results demonstrate how different cellular chaperones can complement one another in order to inhibit harmful protein aggregation. Further studies will be needed to understand the full role of J-domain proteins in preventing tau from accumulating into fibers, as well as their potential as drug targets for developing new treatments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>molecular chaperones</kwd><kwd>protein aggregation</kwd><kwd>Hsp40</kwd><kwd>NMR</kwd><kwd>amyloids</kwd><kwd>tau</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>802001</award-id><principal-award-recipient><name><surname>Rosenzweig</surname><given-names>Rina</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007362</institution-id><institution>Abisch-Frenkel-Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rosenzweig</surname><given-names>Rina</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001735</institution-id><institution>Weizmann Institute of Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wolf</surname><given-names>Sharon Grayer</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Chaperones from different families and classes synergistically target different stages of tau aggregation, thus preventing pathological amyloid formation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tau is an intrinsically disordered protein (IDP) that is highly expressed in neurons and plays essential roles in microtubule self-assembly and stability (<xref ref-type="bibr" rid="bib38">Mandelkow and Mandelkow, 2012</xref>), axonal transport (<xref ref-type="bibr" rid="bib23">Gustke et al., 1994</xref>), and neurite outgrowth (<xref ref-type="bibr" rid="bib7">Biernat and Mandelkow, 1999</xref>). Tau binds to microtubules via its central microtubule-binding repeat (MTBR) domain (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), an interaction that is modulated by post-translational modifications (PTMs). Aberrant PTMs such as hyperphosphorylation and acetylation (<xref ref-type="bibr" rid="bib24">Hanger et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Morris et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Cook et al., 2014</xref>) were suggested to decrease the affinity of tau to microtubules, thus subsequently reducing microtubule stability. In addition, when tau dissociates from microtubules, it can form oligomers with the potential to disrupt cellular membranes, thereby impairing synaptic and mitochondrial functions, before ultimately forming amyloid fibers (<xref ref-type="bibr" rid="bib59">Shafiei et al., 2017</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Interaction of chaperones with monomeric tau.</title><p>(<bold>A</bold>) Domain organization of the longest splice isoform of tau protein (2N4R) and the short variant (4R/K18) containing only the microtubule binding repeats (MBTRs). The location of the two N-terminal inserts (N1 and N2) and the polyproline region (PPR) is indicated. The MTBR region of tau consists of four partially repeated sequences, R1 to R4, with the PHF6* and PHF6 aggregation-driving hexapeptides highlighted in gray. (<bold>B, C</bold>) ThT-based aggregation assay of 2N4R (<bold>B</bold>) and 4R (<bold>C</bold>) tau variants (10 µM) in the presence of 5 µM HSPB1 (green), DNAJA2 (purple), or DNAJB1 (blue) chaperones. The inset shows tau aggregation profiles in the presence of twofold excess (20 µM) of the same chaperones, showing complete inhibition over the course of the experiment. Representative data from three independent experiments is shown. (<bold>D</bold>) Tau<sup>4R</sup> binding profiles to HSPB1 (green), DNAJA2 (purple), and DNAJB1 (blue) chaperones, probed by NMR. Changes in NMR intensity ratios (I/I<sub>0</sub>) upon addition of twofold excess of each chaperone are plotted as a function of tau<sup>4R</sup> residue number. The gray boxes represent the positions of the tau PHF6* and PHF6 aggregation-prone motifs. Values lower than 0.5 indicate intermolecular interactions.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Aggregation assay of 2N4R and 4R tau variants.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69601-fig1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>NMR binding experiments of tau<sup>4R</sup> to HSPB1, DNAJB1, and DNAJA2 chaperones.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69601-fig1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Interaction of chaperones with monomeric tau.</title><p><sup>1</sup>H-<sup>15</sup>N TROSY-HSQC spectra of full-length tau (2N4R, <bold>A</bold>) or tau<sup>4R</sup> (<bold>B</bold>) alone (black) and upon addition of twofold excess of HSPB1 (green), DNAJA2 (purple), or DNAJB1 (blue) chaperones. Residues from the PHF6 and PHF6* aggregation-prone regions, which interact with HSPB1 and DNAJA2 chaperones, are indicated on the tau spectra.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig1-figsupp1-v2.tif"/></fig></fig-group><p>These abnormal forms of tau are thought to play a key role in the pathogenesis of various human tauopathies, including Alzheimer’s disease (AD), frontotemporal dementias, and progressive supranuclear palsy (<xref ref-type="bibr" rid="bib3">Ballatore et al., 2007</xref>). In such cases, tau forms large intracellular aggregates, termed neurofibrillary tangles, whose abundance and localization in the brain correlates with cognitive decline (<xref ref-type="bibr" rid="bib3">Ballatore et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Brunello et al., 2020</xref>). It is still unclear, however, if the fibrils themselves are the neurotoxic species or whether prefibrillar soluble aggregates and oligomers of tau promote neuronal death by spreading tau pathogenicity from cell to cell in a prion-like manner.</p><p>Chaperone machineries, and in particular members of the Hsp70 and the ATP-independent, small heat shock protein (sHSP) families, engage with tau during these pathogenic events, counteracting its aggregation into amyloids and targeting the misfolded species for degradation (<xref ref-type="bibr" rid="bib15">Dou et al., 2003</xref>; <xref ref-type="bibr" rid="bib66">Voss et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Petrucelli et al., 2004</xref>; <xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib10">Caballero et al., 2021</xref>). Moreover, in various cellular models, increased chaperone levels were shown to play an important role in tau cellular homeostasis by promoting tau solubility and microtubule binding while reducing the levels of pathological tau species (<xref ref-type="bibr" rid="bib15">Dou et al., 2003</xref>; <xref ref-type="bibr" rid="bib52">Perez et al., 1991</xref>; <xref ref-type="bibr" rid="bib55">Renkawek et al., 1994</xref>; <xref ref-type="bibr" rid="bib13">Dabir et al., 2004</xref>; <xref ref-type="bibr" rid="bib58">Sahara et al., 2007</xref>; <xref ref-type="bibr" rid="bib28">Jinwal et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Shimura et al., 2004</xref>). The chaperones do so by specifically recognizing the six-residue aggregation-prone regions located at the start of the second and third repeats in the MTBR domain (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Freilich et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Baughman et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Weickert et al., 2020</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). These two motifs, <sup>275</sup>VQIINK<sup>280</sup> and <sup>306</sup>VQIVYK<sup>311</sup> (also called PHF6* and PHF6, respectively), are susceptible to the formation of β-sheet structures that have been found to be a prerequisite for tau aggregation (<xref ref-type="bibr" rid="bib65">von Bergen et al., 2000</xref>; <xref ref-type="bibr" rid="bib45">Mukrasch et al., 2005</xref>).</p><p>Despite both Hsp70 and HSPB1 chaperones recognizing the same regions, their tau aggregation-prevention mechanisms have been found to be markedly different. Hsp70 interaction with tau suppresses the formation of aggregation-prone tau nuclei and sequesters tau oligomers and fibrils (<xref ref-type="bibr" rid="bib5">Baughman et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Patterson et al., 2011</xref>), thereby neutralizing their ability to damage membranes and seed further tau aggregation (<xref ref-type="bibr" rid="bib34">Kundel et al., 2018a</xref>). In contrast, HSPB1 was shown to delay tau fiber formation by weakly interacting with early species in the aggregation reaction (<xref ref-type="bibr" rid="bib5">Baughman et al., 2018</xref>). Thus, it would appear that different cellular chaperones can bind to distinct tau species and affect tau homeostasis in different ways.</p><p>Excitingly, though, HSPB1 is not the only ATP-independent chaperone reported to interfere with the tau aggregation pathway – members of the Hsp40 family (also known as J-domain proteins [JDPs]) have also recently been reported to affect tau aggregation in the cell (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Brehme et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Fontaine et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Hou et al., 2020</xref>).</p><p>JDPs are a diverse group of proteins that function as co-chaperones of the Hsp70 machinery, and are responsible both for selecting and delivering clients to the chaperones, and stimulating Hsp70 ATPase activity, thereby activating the chaperone cycle. These multidomain proteins are all structurally characterized by the conserved signature J-domain, essential for stimulation of Hsp70 ATPase activity (<xref ref-type="bibr" rid="bib33">Kityk et al., 2018</xref>). In addition, canonical class A and B JDPs also comprise a regulatory glycine‐rich (GF) region adjacent to the N-terminal J-domain (<xref ref-type="bibr" rid="bib17">Faust et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Karamanos et al., 2019</xref>), two structurally similar C-terminal β‐barrel domains (CTDI and CTDII) containing the substrate binding region, and a dimerization domain (<xref ref-type="bibr" rid="bib29">Kampinga and Craig, 2010</xref>; <xref ref-type="bibr" rid="bib57">Rosenzweig et al., 2019</xref>). Class A JDPs further contain a zinc-finger-like region (ZFLR) protruding from CTDI.</p><p>Recently, several studies have indicated that JDPs can also function as bona fide chaperones, utilizing holdase activity to prevent the aggregation of their client proteins (<xref ref-type="bibr" rid="bib2">Ayala Mariscal and Kirstein, 2021</xref>).</p><p>DNAJA2, a member of this JDP family, was recently identified as a potent suppressor of tau aggregation, capable of effectively preventing the seeding of tau and formation of amyloids in cells (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Abisambra et al., 2012</xref>), with DNAJA2 levels being selectively increased in AD patient neuronal cells (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>). Additionally, it was recently shown that, along with the Hsp70 system, DNAJB1, a class B JDP, can break apart tau amyloid fibers extracted from AD brain tissues (<xref ref-type="bibr" rid="bib48">Nachman et al., 2020</xref>).</p><p>Little is known, however, regarding how these co-chaperones interact with tau or the mechanism by which they modify tau disease-related amyloid states.</p><p>We therefore used NMR spectroscopy, in combination with kinetic aggregation assays, to elucidate the effect of the DNAJA2 and DNAJB1 chaperones on tau aggregation. We found that the aggregation-prevention mechanisms of DNAJB1 and DNAJA2 are strikingly different from that of HSPB1 holdase chaperone. Moreover, we found that the two Hsp40 family members also diverge in their interactions with tau, whereas DNAJA2 interacts with all species along the tau aggregation pathway, including inert tau monomers, DNAJB1 only interacts with aggregation-prone tau conformers, such as seeding competent species or mature fibers.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The chaperones slow down tau aggregation and bind tau</title><p>We first investigated the effect of DNAJA2 and DNAJB1 on the fibril formation of full-length tau (2N4R) and compared it to that of HSPB1, a well-characterized suppressor of tau aggregation. Tau aggregation was monitored using Thioflavin-T (ThT) fluorescence (<xref ref-type="bibr" rid="bib6">Biancalana and Koide, 2010</xref>). The 3D GXG variant of HSPB1 (22) was used to mimic the fully activated dimeric form of the chaperone. As expected, the addition of HSPB1 significantly inhibited tau fiber formation, in agreement with previous reports (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Freilich et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Baughman et al., 2018</xref>). Interestingly, addition of DNAJA2 and DNAJB1 chaperones also completely inhibited the formation of tau fibrils for over 16 hr (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), with no observable ThT signal being detected over this length of time. Similar results were obtained with the shorter tau construct tau<sup>4R</sup> (residues 244–372) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), which forms the core of tau filaments and nucleates tau aggregation (<xref ref-type="bibr" rid="bib4">Barghorn et al., 2004</xref>). Despite the faster aggregation kinetics of tau<sup>4R</sup> relative to the full-length tau (t½ ≈ 110 min vs. t½ ≈ 340 min), the presence of even a sub-stoichiometric concentration of either of the three molecular chaperones (DNAJB1, HSPB1, or DNAJA2) fully suppressed aggregation for the duration of the experiment (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>As all three chaperones are able to suppress tau aggregation, we next aimed to understand the mechanisms by which they do so.</p><p>In order to unravel the mechanism of aggregation prevention, we first identified the binding sites for the three chaperones on tau. To this end, we recorded <sup>1</sup>H-<sup>15</sup>N HSQC spectra of either <sup>15</sup>N-tau or <sup>15</sup>N-tau<sup>4R</sup> in the absence and presence of each chaperone. Upon addition of HSPB1, we observed significant peak broadening of tau residues 275–280 and 306–311, which correspond to the PHF6* and PHF6 motifs (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), in agreement with previous reports (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Freilich et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Baughman et al., 2018</xref>). Notably, the PHF6 motifs, which are the most hydrophobic regions within tau, are also the preferential binding sites for the major ATP-dependent chaperone families, such as Hsp70 and Hsp90 (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>). A similar preference for the PHF6 and PHF6* motifs was also found for DNAJA2, with residues 275–284 and 306–320 showing significant peak broadening (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Surprisingly, however, DNAJB1 showed no significant binding to tau, despite efficiently suppressing amyloid formation (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p></sec><sec id="s2-2"><title>Binding to tau fibrils</title><p>As DNAJB1 efficiently prevented tau aggregation in both full-length and tau<sup>4R</sup> experiments, yet showed no detectable binding to the monomers, we hypothesized that it functions, instead, through association with preformed tau fibers. In fact, a similar behavior was recently reported for DNAJB1 in the case of α-synuclein, where the chaperone displayed a remarkable preference (&gt;300-fold) toward the amyloid state of α-synuclein over the monomer (<xref ref-type="bibr" rid="bib69">Wentink et al., 2020</xref>).</p><p>We therefore checked whether DNAJB1 interacts with preformed tau<sup>4R</sup> fibrils using co-sedimentation experiments. Indeed, a large portion of DNAJB1 was detected in the insoluble fraction together with tau<sup>4R</sup> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), indicating a strong interaction between tau fibrils and the chaperone. Co-sedimentation experiments with DNAJA2 and HSPB1 showed that also DNAJA2 co-precipitated with tau fibers, whereas HSPB1 was mainly found in the soluble fraction and only marginally interacted with tau amyloids (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similar results were also obtained with fluorescence anisotropy, resulting in an affinity (dissociation constant) for tau<sup>4R</sup> fibrils of 1.7 ± 0.2 µM (mean ± s.e.m.) for DNAJB1 and of 7.6 ± 0.6 µM for DNAJA2 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In contrast, the affinity of HSPB1 for tau fibers was outside our experimental concentration range.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Interaction of chaperones with preformed tau fibrils.</title><p>(<bold>A</bold>) Co-sedimentation of preformed tau amyloid fibrils (10 μM) in the presence of 10 μM DNAJB1, DNAJA2, or HSPB1 chaperones. SDS-PAGE of the supernatant (S) and pellet (P) fractions following ultracentrifugation is shown. (<bold>B</bold>) Fluorescence anisotropy assays of tau fibers binding to DNAJB1 (blue) or DNAJA2 (purple). Data points represent the means of three independent measurements (with standard deviations), with the K<sub>D</sub>s for DNAJB1 and DNAJA2 being 1.7 ± 0.2 µM and 7.6 ± 0.6 µM, respectively. (<bold>C</bold>) Fluorescence anisotropy assays of monomeric tau binding to HSPB1 (green), DNAJB1 (blue), or DNAJA2 (purple). The K<sub>D</sub>s were calculated as 250 ± 26 µM for HSPB1 and 43 ± 8 µM for DNAJA2. No binding was observed for DNAJB1. Data are mean ± s.e.m. (n = 3). (<bold>D</bold>) Representative negative stain electron microscopy micrographs of preformed tau fibers alone or upon incubation with 1:1 molar ratio of HSPB1, DNAJA2, or DNAJB1 chaperones. The asterisks show the position of HSPB1 chaperone clusters. White bar is 200 nm.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Interaction of chaperones with preformed tau fibrils.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69601-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig2-v2.tif"/></fig><p>The selective interaction of DNAJB1 and DNAJA2 chaperones with tau fibers was also observed by negative stain electron microscopy (EM). Here, tau alone formed characteristic long twisted filaments with a periodicity of 50–100 nm (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), consistent with previous observations (<xref ref-type="bibr" rid="bib19">Fitzpatrick et al., 2017</xref>). Upon addition of HSPB1 chaperone to the fibers, no changes to fiber length or morphology were detected, in agreement with our co-sedimentation assays that showed no binding of HSPB1 chaperone to the preformed fibers. HSPB1 itself, however, generated large protein assemblies that can be seen next to the fibers in the EM images (marked by *).</p><p>Addition of DNAJB1 or DNAJA2, on the other hand, caused visible change in the appearance of the fibers, generating straighter, less twisted filaments decorated by periodically bound chaperones (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The overall length of the fibers, however, did not change substantially, and also smaller tau fragments were not observed in our EM images, indicating that DNAJB1 and DNAJA2 do not enhance fiber breakage or fragmentation upon binding. In summary, HSPB1 only binds tau<sup>4R</sup> monomers, DNAJB1 interacts with tau<sup>4R</sup> fibrils, whereas DNAJA2 binds both monomers and fibers (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>).</p></sec><sec id="s2-3"><title>Each chaperone suppresses a specific subset of microscopic processes in the tau aggregation reaction</title><p>We were next interested to see how the different tau binding modes of the three chaperones affect their respective aggregation-prevention mechanisms. We therefore performed a series of aggregation kinetics experiments, varying the concentrations of the chaperones while maintaining a constant concentration of tau<sup>4R</sup>.</p><p>In the absence of chaperones, the aggregation of tau<sup>4R</sup> has previously been reported to occur through the following microscopic steps: primary nucleation, fibril growth through the addition and rearrangement of monomers (saturating elongation), and fiber fragmentation (<xref ref-type="bibr" rid="bib35">Kundel et al., 2018b</xref>; <xref ref-type="bibr" rid="bib71">Yao et al., 2020</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). To confirm that this is indeed the aggregation mechanism for tau<sup>4R</sup> under our experimental conditions, we recorded aggregation kinetics data at various concentrations of monomeric tau<sup>4R </sup>(2.5–40 µM; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The half-saturation times (half-times) were then extracted and analyzed as a function of the concentration of tau<sup>4R</sup> monomer in accordance with a protocol by <xref ref-type="bibr" rid="bib40">Meisl et al., 2016</xref>, allowing us to calculate the scaling exponent. This was found to be −0.34 ± 0.04, which was consistent with a dominant primary nucleation pathway and a contribution stemming from the presence of fibril fragmentation (<xref ref-type="bibr" rid="bib35">Kundel et al., 2018b</xref>; <xref ref-type="bibr" rid="bib71">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Shammas et al., 2015</xref>; see Materials and methods for more detail). In addition, a positive curvature of these double-logarithmic plots indicated the presence of saturation effects in the dominant mechanism (<xref ref-type="bibr" rid="bib40">Meisl et al., 2016</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>).</p><p>Tau<sup>4R</sup> aggregation kinetics data in the absence (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) and presence of aggregation seeds (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>) were next globally fit, assuming a nucleus size of two tau<sup>4R</sup> monomers, to extract the kinetic rates for nucleation, elongation, and fragmentation, as well as the saturation constant (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>).</p><p>All chaperones caused a concentration-dependent retardation of tau aggregation at sub-stoichiometric concentrations (<xref ref-type="fig" rid="fig3">Figure 3</xref>). To understand the effect of the chaperones at the microscopic level, we fit the data to the kinetic model of tau aggregation using the kinetic parameters derived in the absence of chaperones. In order to determine which step in the aggregation mechanism is most likely affected by each of the chaperones, we only allowed an individual kinetic rate to vary in each of the analyses (see Materials and methods for detail). As the addition of any of the chaperones to preformed tau fibrils did not change the overall fibril length (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), we could further assume that the chaperones have no effect on tau fragmentation rates (k<sub>m</sub>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>HSPB1, DNAJA2, and DNAJB1 chaperones affect different microscopic steps in the aggregation process.</title><p>Kinetic profiles of the aggregation of 10 μM of tau in the absence (black) and presence of increasing concentrations of (<bold>A</bold>) HSPB1 chaperone (1, 2, 5, and 10 μM; dark to light green), (<bold>B</bold>) DNAJA2 (0.5, 1, 2.5, 5, 7.5, and 10 μM; dark to light purple), or (<bold>C</bold>) DNAJB1 (0.5, 1, 2.5, 5, 7.5, and 10 μM; dark to light blue). Open circles represent experimental data, and solid lines represent the fit of the kinetic profiles where only the primary nucleation (k<sub>n</sub>, left) or elongation (k<sub>p</sub>, right) pathways are inhibited. Residuals of the fits are shown under each panel. The changes in the aggregation kinetics caused by HSPB1 fit well with the elongation rate being primarily affected by the chaperone (<bold>A</bold>, right) whereas the changes in tau aggregation kinetics caused by DNAJB1 can be best described by the reduction of primary nucleation rates (<bold>C</bold>, left). In the case of DNAJA2, the changes in aggregation kinetics cannot be well described by the delay of only primary nucleation (<bold>B</bold>, left) or only elongation (<bold>B</bold>, middle) rates. There is good agreement, however, between the experimental data and fits to the integrated rate law of combined seeded and unseeded, in which primary nucleation, elongation, and fragmentation events have been considered simultaneously (<bold>B</bold>, right). Data points represent the means of 3–5 independent measurements. (<bold>D</bold>) The changes in microscopic nucleation (top) and elongation (bottom) rate constants as a function of the concentration of the molecular chaperones, relative to tau alone.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Kinetic profiles of tau aggregation in the presence of molecular chaperones.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69601-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Global fitting of tau aggregation data.</title><p>(<bold>A</bold>) A plot of the aggregation reaction half-times versus the initial monomer concentration used to narrow down the aggregation mechanism of tau (<xref ref-type="bibr" rid="bib40">Meisl et al., 2016</xref>). Half-times were calculated from three independent experiments of unseeded tau aggregation, as shown in (<bold>B</bold>). To extract the scaling factor (γ), the half-times (<italic>t</italic><sub>1/2</sub>) of the aggregation reaction were plotted versus the tau monomer concentration on a double logarithmic plot with the slope of this plot providing the scaling exponent (log(<italic>t</italic><sub>1/2</sub>) = γlog(<italic>m</italic><sub>0</sub>) + constant). By using the rate laws for the time evolution of aggregate mass, γ can be related to the reaction orders for each of the models. The scaling factor for tau aggregation was calculated to be −0.34 ± 0.04, with −0.5 &lt; γ &lt; 0, indicating primary nucleation and fragmentation as the correct model. Furthermore, the deviation of the points from a straight line shows that γ is dependent on the monomer concentration, with positive curvature indicating the presence of saturating elongation (<xref ref-type="bibr" rid="bib40">Meisl et al., 2016</xref>). (<bold>B, C</bold>) Kinetic profiles of the concentration-dependent aggregation of tau<sup>4R</sup> at concentrations of 2.5, 5, 7.5, 10, 15, 20, and 30 μM, initiated by the addition of 0.5 molar equivalents of heparin (<bold>B</bold>) or 1% seeds (<bold>C</bold>), and monitored by Thioflavin-T (ThT) fluorescence (open circles). Continuous lines represent the global fitting of the data to the integrated rate laws (see equations in the Materials and methods section). (<bold>D</bold>) Schematic of microscopic steps during tau aggregation and their corresponding rate constants as obtained from the fits (see Materials and methods for detail). k<sub>n</sub> is the rate of nucleation, k<sub>p</sub> is the rate of elongation, K<sub>E</sub> is the critical concentration for saturated elongation, and k<sub>m</sub> is the rate of fibril fragmentation. Nucleus size was assumed to be 2 (n<sub>c </sub>= 2) (<xref ref-type="bibr" rid="bib71">Yao et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Shammas et al., 2015</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effect of chaperones on tau aggregation kinetics.</title><p>(<bold>A</bold>) Global fit analysis of tau aggregation (black) in the presence of increasing concentrations of HSPB1 chaperone (1, 2, 5, and 10 μM; dark to light green), constrained such that both the nucleation and elongation rates (k<sub>n</sub>, k<sub>p</sub>) were free fit parameters. Open circles represent experimental data, and solid lines represent the fits. The residuals of the fits do not become significantly smaller compared to fits where only elongation rates (k<sub>p</sub>) were allowed to vary (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Thus, HSPB1 mainly affects the rate of elongation in tau aggregation kinetics and not the rate of nucleation. (<bold>B</bold>) Global fit analysis of tau aggregation (black) in the presence of increasing concentrations of DNAJB1 chaperone (0.5, 1, 2.5, 5, 7.5, and 10 μM; dark to light blue), constrained similarly as in (<bold>A</bold>). DNAJB1 mainly affects the rate of nucleation with a minor effect on the elongation rates. (<bold>C</bold>) Global fit analysis of tau aggregation alone and in the presence of increasing concentrations of DNAJA2 chaperone (0.5, 1, 2.5, 5, 7.5, and 10 μM; dark to light purple) for seeded (left) and unseeded (right) experiments. Seeded experiments were fit globally, only allowing variation in the elongation rates, as the nucleation rates are negligible under seeding conditions. Changes in elongation rates due to the presence of DNAJA2 chaperone (summarized in <xref ref-type="fig" rid="fig3">Figure 3D</xref>) were then used as constants in the global fit analysis of the unseeded experiments, while the nucleation rates were allowed to vary. This approach allowed us to derive the changes in both the nucleation and elongation rates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig3-figsupp2-v2.tif"/></fig></fig-group><p>Upon fitting HSPB1 aggregation-prevention data, only a poor agreement was achieved when allowing the perturbation of primary nucleation rates (k<sub>n</sub>) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Given the fact that HSPB1 binds tau monomers, the relatively moderate effect on tau primary nucleation was somewhat surprising as monomer binding should inhibit both nucleation and elongation. In contrast, fitting the fiber elongation rate (k<sub>p</sub>) provided a significantly better description of the kinetic data (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), indicating an order of magnitude reduction of this rate (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Moreover, even when allowing the variation of both the nucleation and elongation rates (k<sub>n</sub> and k<sub>p</sub>) in the fit, only the elongation rates were reduced in the presence of HSPB1 chaperone, while the nucleation rates remained unchanged (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>, <xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>The effect of DNAJA2 on tau aggregation could neither be described by the reduction of nucleation rates nor elongation rates alone (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), which is not entirely surprising, given that the chaperone can bind to both monomeric tau and fibrils (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). In general, DNAJA2 has at least two distinct pathways to impact aggregation, namely by (i) reducing the amount of monomeric tau accessible for nucleation and elongation and (ii) lowering the potency of fibrils to grow. In order to determine which rates are affected by the chaperone, we recorded an additional set of kinetic measurements in the presence of DNAJA2 chaperone, this time with the aggregation being initiated by tau fiber seeds. In the presence of seeds, tau primary nucleation events are negligible, thus allowing us to estimate the effect of the DNAJA2 chaperone only on rate constants of elongation and fragmentation (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>). Using a global fit of the unseeded and seeded aggregation kinetics, we were then able to determine the effect of DNAJA2 on the nucleation and elongation rates (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref> and <xref ref-type="fig" rid="fig3">Figure 3D</xref>). Combined, these results show a substantial perturbation of both tau nucleation and elongation rates by the DNAJA2 chaperone (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), indicating that this chaperone affects the aggregation process in more intricate ways than HSPB1.</p><p>Surprisingly, the effect of DNAJB1 on tau aggregation was best described by its ability to reduce the rates of primary nucleation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, left) and, only to a lesser extent, fiber elongation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, right). This ability of the DNAJB1 chaperone to effectively inhibit the rate of tau<sup>4R</sup> primary nucleation was unexpected as primary nucleation involves interaction between tau monomers, yet no interaction between DNAJB1 and this species of tau was observed in our NMR experiments.</p></sec><sec id="s2-4"><title>Two conformations of monomeric tau</title><p>The effect of DNAJB1 on tau<sup>4R</sup> nucleation, despite its inability to interact with monomeric tau<sup>4R</sup>, can, however, be reconciled by the recent finding that soluble monomeric tau<sup>4R</sup> exists in two conformational ensembles – an ensemble that does not spontaneously aggregate (‘inert’ tau monomer) and a seed-competent monomer that triggers the spontaneous aggregation of tau (<xref ref-type="bibr" rid="bib41">Mirbaha et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>). It is therefore possible that DNAJB1 only identifies and interacts with the ‘aggregation-prone’ tau species and not the inert monomers.</p><p>Such seed-competent species have been proposed to be readily populated in tauopathy-associated tau mutants (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), and can be generated in vitro by addition of polyanions such as heparin (<xref ref-type="bibr" rid="bib16">Eschmann et al., 2017</xref>). Unfortunately, the addition of heparin causes the rapid formation of tau fibers, thus preventing a detailed structural investigation of the seed-competent ensemble using NMR spectroscopy.</p><p>Yet, whereas tau<sup>4R</sup> is inaccessible under conditions at which it rapidly aggregates, the rate of tau fibrillization can be tuned by altering the concentration of heparin present in the aggregation reaction. Low concentrations of heparin enhance the rate of fiber formation, whereas higher heparin concentrations potentially inhibit it (<xref ref-type="bibr" rid="bib54">Ramachandran and Udgaonkar, 2011</xref>). We therefore performed aggregation kinetics at different heparin concentrations (0.1–40 µM) to identify the conditions at which tau aggregation is sufficiently slow to permit NMR experiments. We found that heparin increased the rate of fiber formation up to a sub-stoichiometric concentration of 1 µM (1:0.1 tau:heparin) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Above this threshold, further addition of heparin in fact slowed tau aggregation in a dose-dependent manner. At a one- to fourfold excess of heparin (10–40 µM), we found that tau amyloid formation was arrested for over 2 hr (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). An equimolar concentration of heparin to tau was therefore used to generate a soluble, aggregation-prone tau species (<xref ref-type="bibr" rid="bib41">Mirbaha et al., 2018</xref>) that does not aggregate and is therefore amenable for NMR experiments.</p><p>We then monitored chaperone binding to this tau species by recording <sup>1</sup>H-<sup>15</sup>N HSQC spectra for <sup>15</sup>N-tau-heparin complex alone, and upon addition of DNAJB1, DNAJA2, and HSPB1 chaperones to the mixture (<xref ref-type="fig" rid="fig4">Figure 4</xref>). To map the binding sites for the chaperones on this heparin-bound, aggregation-prone tau species, we first had to assign its spectrum. HNCA, CBCA(CO)NH, HN(CA)CO, and HNCO 3D NMR experiments were recorded, and assignments were obtained for 88% of the non-proline residues. Heparin binding resulted in chemical shift perturbations (CSPs) to the NMR spectrum of tau<sup>4R</sup>, mainly in the R1, R2, and PHF6* regions (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). No changes were observed to the overall dispersion of the spectrum, indicating that heparin binding does not induce global folding of tau, in agreement with previous findings (<xref ref-type="bibr" rid="bib45">Mukrasch et al., 2005</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Interaction of chaperones with aggregation-prone tau species.</title><p>(<bold>A</bold>) Overlay of two-dimensional <sup>1</sup>H-<sup>15</sup>N NMR spectra of tau in the absence (black) and presence of heparin (orange). Heparin binds mainly to the R1, R2, and PHF6* regions (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), with no changes observed to the overall dispersion of the spectra, indicating that heparin binding does not result in global folding of tau. (<bold>B</bold>) Residue-resolved NMR signal attenuation (I/I<sub>0</sub>) of tau in complex with heparin upon addition of one molar equivalent of DNAJB1 (blue), DNAJA2 (purple), or two molar equivalents of HSPB1 (green). Gray boxes represent the positions of tau PHF6* and PHF6 aggregation-prone motifs in tau. Unlike in the case of tau monomer, DNAJB1 interacts strongly with this aggregation-prone species, while HSPB1 chaperone does not. (<bold>C</bold>) Residue-resolved backbone amide NMR signal attenuation (I/I<sub>0</sub>) of tau P301S mutant upon addition of two molar equivalents of DNAJB1 (blue), HSPB1 (green), or DNAJA2 (purple) chaperones. Dashed lines represent the same intensity plots for wild-type tau (as in <xref ref-type="fig" rid="fig1">Figure 1D</xref>). Compared to the wild-type, P301S mutant shows increased interaction with DNAJB1.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>NMR binding experiments of tau P301L mutant to HSPB1, DNAJB1, and DNAJA2 chaperones.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69601-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of heparin-bound tau.</title><p>(<bold>A</bold>) Tau aggregation profiles in the presence of increasing concentrations of heparin ranging from 0.1 to 40 μM. Initially, the rate of aggregation increases with the concentration of heparin. At 1 µM heparin, the reaction slows, with higher concentrations (20–40 μM) suppressing aggregation completely for over 2 hr (dark blue to purple curves). (<bold>B</bold>) Chemical shift perturbation plot of tau upon addition of twofold excess of heparin. Heparin binding occurs mainly in repeat 2 (R2) of tau. The gray boxes represent tau PHF6* and PHF6 aggregation-prone motifs. (<bold>C</bold>) Secondary structure propensity plot (<xref ref-type="bibr" rid="bib39">Marsh et al., 2006</xref>) of monomeric tau (black, top) and tau-heparin complex (orange, bottom). (<bold>D</bold>) Differences between secondary chemical shifts of Cα and Cβ resonances relative to their random coil shift (<xref ref-type="bibr" rid="bib70">Wishart and Sykes, 1994</xref>) as a function of residue number for tau (gray) or tau-heparin complex (orange).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Chaperone binding to tau tested at high ionic strength.</title><p>Residue-resolved NMR signal attenuation plot (I/I<sub>0</sub>) of tau in buffer supplemented with 0.3 M KCl, upon addition of twofold molar excess of DNAJB1 (blue), DNAJA2 (purple), or HSPB1 (green) chaperones. Values lower than 0.5 indicate intermolecular interactions. The binding profiles are identical to those obtained at low salt conditions (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Conformations of the various tau species measured through residual dipolar couplings (RDCs).</title><p>(<bold>A, B</bold>) Backbone amide RDCs (<sup>1</sup>D<sub>NH</sub>), collected in 5 mg/mL phage pf1 (<xref ref-type="bibr" rid="bib25">Hansen et al., 1998</xref>) (<bold>A</bold>) or 4.5% (vol/vol) C12E5/n-hexanol (<xref ref-type="bibr" rid="bib50">Otting et al., 2000</xref>) (<bold>B</bold>) alignment media, showing a compaction in the PHF6* and PHF6 repeat regions (highlighted in gray). The 1D <sup>2</sup>H spectra, recorded on the 1000 MHz spectrometer (middle, right), show splitting of 5.4 Hz (<bold>A</bold>) and 17.4 Hz (<bold>B</bold>), respectively. In both alignment media, large RDCs were observed for residues in the PHF6 aggregation-prone repeats, indicating the presence of a compaction of this region. (<bold>C</bold>) <sup>1</sup>D<sub>NH</sub> RDCs measured for 1:1 tau:heparin complex aligned with 16 mg/mL phage pf1. The RDCs show highly decreased values in the PHF6* and PHF6 repeat regions compared to tau alone, indicating an expansion in this region. The 1D <sup>2</sup>H spectra, recorded on the 1000 MHz spectrometer (middle, right, <bold>C</bold>), show splitting of 20.3 Hz, indicating a higher degree of alignment compared to tau alone. (<bold>D, E</bold>) <sup>1</sup>D<sub>NH</sub> RDCs measured for tau<sup>4R</sup> P301L mutant collected in 5 mg/mL phage pf1 (<bold>D</bold>) or 4.5% (vov/vol) C12E5/n-hexanol (<bold>E</bold>) alignment media. Both conditions show lower RDC values in the PHF6* and PHF6 repeat regions compared to wild-type tau<sup>4R</sup> (differences in RDCs between WT tau and the P301L sample are shown underneath each plot), indicating a slightly increased tendency toward an extended structure in this tauopathy-associated mutant. The degree of alignment for the two samples was slightly higher than that of tau<sup>4R</sup>, as indicated by the <sup>2</sup>H splitting (middle, right) of 6.0 Hz (<bold>D</bold>) and 17.7 Hz (<bold>E</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Interaction of chaperones with tauopathy associated tau mutants.</title><p>(<bold>A</bold>) Residue-resolved NMR signal attenuation (I/I<sub>0</sub>) of tau P301L mutant upon addition of two equivalents of DNAJB1 (blue), DNAJA2 (purple), or HSPB1 (green) chaperones. The position of the mutation between repeats 1 and 2 is indicated in red on the domain organization (top). Gray boxes represent the positions of the tau PHF6* and PHF6 aggregation-prone motifs. Dashed lines show the intensity changes for wild-type tau upon interaction with same chaperones. (<bold>B</bold>) Thioflavin-T (ThT)-based aggregation assay of 10 µM tau P301S variant alone (dark red), and in the presence of 5 µM HSPB1 (green), DNAJA2 (purple), or DNAJB1 (blue) chaperones. (<bold>C</bold>) Comparison of aggregation reaction half-times of tau<sup>4R</sup> (gray bars) and P301S tau (dark red bars) variants alone, and in the presence of chaperones. HSPB1 chaperone shows a significant reduction in its aggregation-prevention activity toward the P301S mutant tau compared to wild-type protein. In contrast, DNAJB1 is more efficient in preventing tau P301S aggregation than that of wild-type tau<sup>4R</sup>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig4-figsupp4-v2.tif"/></fig></fig-group><p>With these assignments in hand, we were able to identify that, despite having negligible affinity toward the tau monomer, the DNAJB1 chaperone indeed interacts strongly with the aggregation-prone tau-heparin mixture (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), as we previously predicted. We further mapped this binding to tau residues 275–280 and 305–314 of the PHF6 and PHF6* repeats – the same regions to which both DNAJA2 and HSPB1 bind in the inert, monomeric tau.</p><p>We next tested whether DNAJA2 and HSPB1 interact with the heparin-bound tau. DNAJA2 showed strong binding to the R2 and R3 PHF6* repeats of this aggregation-prone form of tau<sup>4R</sup>, similarly to its interaction with the free monomer (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In contrast, HSPB1 only bound this species weakly, despite previously displaying a strong interaction with free tau<sup>4R</sup>. The lack of interaction between HSPB1 and aggregation-prone tau species explains our previous observation that HSPB1 does not affect the rate of fiber nucleation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), as such an inhibition would require a direct interaction with the aggregate nucleus or aggregation-prone tau.</p><p>Thus, while interacting with the same regions of tau, the three chaperones each display specific preferences for the different tau monomer conformers: HSPB1 interacts solely with tau monomers; DNAJB1 exclusively with the aggregation-prone species; and DNAJA2 with both.</p><p>It was unclear, however, how the chaperones discriminate between the inert form of tau and the aggregation-prone tau-heparin complex.</p></sec><sec id="s2-5"><title>Aggregation-prone tau species</title><p>Secondary-structure propensity analysis (<xref ref-type="bibr" rid="bib39">Marsh et al., 2006</xref>) of free and heparin-bound tau demonstrated that the different chaperone binding profiles cannot be explained by heparin-induced formation of extended β-strand structures in the PHF6 repeats (<xref ref-type="bibr" rid="bib16">Eschmann et al., 2017</xref>) as these regions displayed no increase in secondary-structure propensity upon addition of heparin (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Likewise, no notable changes were observed between the Cα and Cβ secondary chemical shifts patterns of heparin-bound and free tau samples (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>).</p><p>We then set out to determine whether the differences between monomeric tau<sup>4R</sup> and the heparin-tau complex are caused by electrostatic interactions. Heparin is a polyanion with a net charge of −3 per disaccharide at pH 7.0 (or estimated charge density of −6.7 e-/kD; <xref ref-type="bibr" rid="bib37">Lin et al., 2020</xref>). In contrast, tau<sup>4R</sup> has a positive net charge of +9.5, suggesting that the heparin-tau<sup>4R</sup> complex is significantly stabilized by electrostatic attractions. As such, the ability of the chaperones to distinguish between the monomeric and aggregation-prone tau species may be related to simple differences in the net charge of the complex, with heparin binding, for example, reducing electrostatic repulsions that may exist between DNAJB1 and monomeric tau<sup>4R</sup>. Screening any such electrostatic interactions with higher ionic strengths (0.3 M), however, neither facilitated binding between DNAJB1 and tau<sup>4R</sup> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>) nor altered tau<sup>4R</sup> interaction with HSPB1 or DNAJA2 chaperones (compare <xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Similarly, the interaction cannot be explained by attractive electrostatic interactions caused by the negative net-charge of the complex as we did not detect specific binding between heparin and any of the chaperones. Hence, electrostatic interactions cannot explain the different binding profiles of the chaperones to the two tau species.</p><p>A clue to how heparin alters the conformational ensemble of tau<sup>4R</sup> came from a recent structural characterization of patient-derived, seeding-competent tau monomer. This species of tau was reported to have an expanded ensemble with a more exposed PHF6 motif compared to the inert monomeric protein (<xref ref-type="bibr" rid="bib41">Mirbaha et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>). This increased expansion of the PHF6 aggregation motifs was, in turn, suggested to drive the self-assembly and subsequent aggregation of tau (<xref ref-type="bibr" rid="bib31">Kaufman et al., 2017</xref>). Interestingly, binding of heparin to tau was also shown to expand the local conformation of the repeat regions (R2 and R3), thereby making the amyloidogenic PHF6 sequences more accessible (<xref ref-type="bibr" rid="bib16">Eschmann et al., 2017</xref>).</p><p>Indeed, in agreement with previous reports (<xref ref-type="bibr" rid="bib46">Mukrasch et al., 2007</xref>; <xref ref-type="bibr" rid="bib47">Mukrasch et al., 2009</xref>), measurements of one-bond N-H RDCs in tau, which had been partially oriented in either a Pf1 bacteriophage or polyethylene glycol/hexanol alignment medium, showed relatively large H-N RDC values (10–20 Hz) in the PHF6 repeat regions, which can arise from a locally compacted conformation (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3A, B</xref>). Similar analysis of the tau-heparin complex showed only very small RDCs in the PHF6 regions, despite the larger degree of alignment of this complex, indicating a potential expansion of these regions (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3C</xref>). This expansion, and thus the increased accessibility of the PHF6 motif in the heparin-bound state, may therefore be what enables the interaction of DNAJB1 with tau.</p><p>To further test whether the expansion of the PHF6 repeats in the seeding-competent tau species is indeed the discriminating factor for chaperone binding, we monitored the interaction of the three chaperones with P301L/S missense mutations, which are known to cause dominantly inherited tauopathy (<xref ref-type="bibr" rid="bib56">Rizzu et al., 1999</xref>). These tau variants had been shown to contain a higher population of the expanded PHF6 conformation (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), as also seen in our RDC measurements (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D, E</xref>), and could therefore potentially mimic the aggregation-prone tau without requiring the addition of heparin.</p><p>Similarly to what we observed for wild-type tau<sup>4R</sup>, we found that indeed all three chaperones efficiently suppressed the aggregation of these tau mutants (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>), although with reduced efficacy in the case of HSPB1 and higher activity of DNAJB1 (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4C</xref>).</p><p>The interaction of the P301L and P301S familial mutations of tau<sup>4R</sup> with HSPB1, DNAJB1, or DNAJA2 chaperones was then assayed using NMR spectroscopy. In the presence of HSPB1 and DNAJA2, the resulting binding profiles of the two tau variants were very similar to those of wild-type tau, with residues 274–280 and 305–318, corresponding to PHF6* and PHF6 repeats, displaying severe peak broadening (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref>). This similarity to wild-type tau was not unexpected, though, as only a small portion of the P301L/S tau conformational ensemble adopts the extended conformation at any given moment (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Kawasaki and Tate, 2020</xref>). In contrast, DNAJB1, while showing no binding to wild-type tau, did cause noticeable reductions in peak intensities in both PHF6 motifs of the P301S and P301L tauopathy mutants (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A</xref>). Moreover, the degree of observed intensity reduction (31 and 26%) was found to be consistent with the relatively low population of the expanded conformation in tau P301L/S mutants (<xref ref-type="bibr" rid="bib32">Kawasaki and Tate, 2020</xref>; <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3D and E</xref>).</p><p>Thus, DNAJB1 binding to monomeric tau indeed appears to depend on the exposure of the PHF6 region, thereby allowing it to distinguish between inert tau and the aggregation-prone species that eventually leads to amyloid formation.</p></sec><sec id="s2-6"><title>Changes to tau fibers caused by the chaperones</title><p>Our results show that all three chaperones efficiently inhibit tau aggregation via interactions with the hydrophobic aggregation-prone PHF6 repeats. Each of the chaperones interacts with a specific set of tau species, thus slowing down different microscopic processes in the aggregation reaction (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, it remained unclear whether the chaperones also affect the size and/or morphology of tau fibers.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The chaperones change the morphology of tau amyloids.</title><p>(<bold>A–C</bold>) Representative negative stain electron micrographs of end products of the tau aggregation-prevention assays preformed in the presence of indicated concentrations of DNAJA2 (<bold>A</bold>), DNAJB1 (<bold>B</bold>), and HSPB1 (<bold>C</bold>). White bar is 500 nm. Tau<sup>4R</sup> forms long fibrils in the absence of chaperones and is still able to form long, fully developed fibrils in the presence of HSPB1 dimer. It forms smaller oligomeric species in the presence of both DNAJA2 and DNAJB1, indicating that these chaperones maintain much of the protein in a non-fibrillary state. (<bold>D</bold>) Overview of the variety of diverse microscopic mechanisms through which HSPB1, DNAJB1, and DNAJA2 molecular chaperones can suppress tau amyloid formation, as revealed by the binding and kinetic assays in this paper. These results demonstrate that the chaperones have evolved to exploit the different opportunities to modulate tau aggregation by binding to different tau species along the aggregation pathway.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Effect of chaperones on tau fibril mass.</title><p>(<bold>A–C</bold>) Unnormalized tau aggregation kinetics showing the reduction of tau fibril mass by addition of increasing concentrations of DNAJA2 (<bold>A</bold>), DNAJB1 (<bold>B</bold>), and HSPB1 (<bold>C</bold>) chaperones. All three chaperones cause a decrease in overall fibril mass, which can result from a reduction in the number of fibers or in total fibril length. DNAJA2 and DNAJB1 chaperones, which reduce the rates of tau nucleation and elongation, showed significantly higher degree of fibril mass reduction at 1:1 chaperone:tau ratio (96 and 94%, respectively) compared to HSPB1, which only reduced fibril mass by 47%.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Since ThT fluorescence only reports on total fibril mass, with no differentiation to fibril length or number, we turned to EM in order to image the fibers. When adding DNAJA2 at the start of the aggregation reaction, a clear dose-dependent decrease in the density and length of the tau fibrils was observed (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Similarly to DNAJA2, DNAJB1-containing reactions yielded shorter fibrils that further shortened when repeating the experiment with increasing chaperone concentrations (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This result is not unexpected given that these two chaperones also bind to tau<sup>4R</sup> fibers (<xref ref-type="fig" rid="fig2">Figure 2</xref>), which may contribute to the arrest of tau amyloid elongation.</p><p>Interestingly, DNAJA2 was very efficient in reducing both the size and amount of formed tau fibers, and even at the sub-stoichiometric concentration of 0.1:1 DNAJA2:tau, a significant reduction in fiber length was observed. At a ratio of 0.25:1 DNAJA2:tau, the majority of fibers were between 0.5 and 2.0 µm long, and at 0.5:1 DNAJA2:tau the fibers were too short to be detected (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). These results were also in agreement with our kinetic measurements at 0.5:1 DNAJA2:tau ratio, which showed an 88% reduction in fibril mass (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Thus, the ability of DNAJA2 chaperone to interact with all tau species and to prevent both elongation and nucleation rates makes it a potent suppressor of tau aggregation. DNAJB1, which does not interact with tau monomers, was less effective than DNAJA2 in reducing fiber size and mass (67% reduction; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), and at 0.5:1 DNAJB1:tau the fibers were still visible. These were, however, significantly shortened, with sizes ranging from 0.2 to 1.0 µm, and at a stoichiometric ratio of 1:1 no fibers were observed (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><p>HSPB1 chaperone, on the other hand, affected fiber formation differently when added at the start of the tau aggregation reaction. While a clear dose-dependent decrease in the amount of the tau fibrils was observed (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), unlike DNAJB1 and DNAJA2, HSPB1 was unable to completely suppress the formation of fibers at sub-stoichiometric concentrations. Even in the presence of twofold excess of HSPB1 chaperone, a few fibers per micrograph were still observed, which, interestingly, were somewhat shorter and straighter in appearance compared to the long twisted fibrils of tau alone (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Although the reduced elongation rate in the presence of HSPB1 decelerates the aggregation process, HSPB1 only has a limited effect on the final fiber mass, as also evident in our kinetic measurements, showing only 45% reduction in fibril mass even at equimolar HSPB1:tau concentrations. Thus, the weak interaction of HSPB1 with tau monomers along with its limited ability to only slow down the fibril elongation rate is not sufficient to efficiently prevent tau incorporation into the amyloid fibers.</p><p>Thus, DNAJB1 and DNAJA2 chaperones, which bind to both aggregation-prone tau species and fibers, are significantly more efficient in preventing the formation of mature fibers than HSPB1, which can only bind to tau monomers.</p></sec><sec id="s2-7"><title>Chaperone interactions with tau</title><p>Overall it appears that the DNAJB1 and DNAJA2 chaperones, despite being very similar in structure, display distinct differences in their interaction with tau. While DNAJA2 binds to all tau species – monomers, aggregation-prone tau, and fibers – DNAJB1 does not bind at all to inert tau monomers, but interacts strongly with the aggregation-prone species as well as mature fibers.</p><p>This disparity between the chaperones could be explained by utilization of different structural domains to recognize the various tau species; however, no structural information is currently available for either DNAJA2 or DNAJB1 in complex with tau<sup>4R</sup>. We therefore utilized NMR to map the binding sites on the chaperones for the various tau species.</p><p>Both DNAJA2 and DNAJB1 are homodimeric proteins comprising an eponymous N-terminal JD that is essential for Hsp70 activation, two putative substrate binding domains, CTDI and CTDII, and a C-terminal dimerization domain. In addition, DNAJA2, as all class A JDPs, has a ZFLR insertion in CTDI (<xref ref-type="bibr" rid="bib29">Kampinga and Craig, 2010</xref>; <xref ref-type="bibr" rid="bib2">Ayala Mariscal and Kirstein, 2021</xref>; <xref ref-type="bibr" rid="bib27">Jiang et al., 2019</xref>), while DNAJB1 has an autoinhibitory GF region connecting the JD to CTDI and blocking premature interaction of Hsp70 with the JD (<xref ref-type="bibr" rid="bib17">Faust et al., 2020</xref>).</p><p>Due to the large size of the DNAJA2 dimer (90 kDa), which hampers NMR experiments, we used a monomeric version of Ydj1, a DNAJA2 homologue from <italic>Saccharomyces cerevisiae</italic>, that contains only the substrate binding and ZFLR domains (<xref ref-type="bibr" rid="bib36">Li et al., 2003</xref>). This construct (27 kDa) of <sup>2</sup>H, <sup>15</sup>N-labeled DNAJA2(Ydj1)<sup>111-351</sup> was far more amenable to NMR and, as previously reported, gave a high-quality <sup>1</sup>H-<sup>15</sup>N HSQC-TROSY spectrum (<xref ref-type="bibr" rid="bib27">Jiang et al., 2019</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Addition of twofold excess of tau<sup>4R</sup> caused CSPs in the first DNAJA2 substrate-binding domain (<xref ref-type="bibr" rid="bib36">Li et al., 2003</xref>), located in CTDI (<xref ref-type="fig" rid="fig6">Figure 6A, C</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Specifically, tau<sup>4R</sup> (most likely via the hydrophobic PHF6 and PHF6* motifs) binds to a hydrophobic pocket located between β-strands 1 and 2 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, colored purple). The binding was in fast exchange, and no reduction in peak intensities to DNAJA2(Ydj1)<sup>111-351</sup> residues was observed (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), in agreement with the relatively low affinity of DNAJA2 for monomeric tau (43 µM, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). DNAJB1, despite its CTDI having 56% identity to the CTDI tau-binding region of DNAJA2, showed no interaction with the monomeric tau (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E, F</xref>), as previously seen from the tau side (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mapping DNAJA2 and DNAJB1 chaperone binding to tau species.</title><p>(<bold>A</bold>) Combined amide chemical shift perturbations between free DNAJA2(Ydj1)<sup>111-351</sup> and DNAJA2(Ydj1)<sup>111-351</sup> bound to unlabeled tau. The domain organization of DNAJA2 is indicated at the bottom. Monomeric tau binds to the C-terminal domain I (CTDI) of DNAJA2, but not to the zinc-finger-like region (ZFLR) insertion. (<bold>B</bold>) Residue-resolved backbone amide NMR signal-attenuation (I/I<sub>0</sub>) plot for DNAJA2(Ydj1)<sup>111-351</sup> in complex with aggregation-prone tau species, generated by addition of twofold excess heparin. The binding is primarily to the C-terminal domain II (CTDII) of DNAJA2. (<bold>C, D</bold>) Structural representation of DNAJA2 chaperone, with residues showing significant chemical shift perturbations (CSPs) upon binding to monomeric tau (from panel <bold>A</bold>) highlighted in purple (<bold>C</bold>), and residues displaying significant decreases in peak intensities upon binding to aggregation-prone tau species colored pink (<bold>D</bold>). (<bold>E</bold>) No changes in signal intensity are detected in the CTDs of DNAJB1 (residues 154–341) upon addition of twofold excess of monomeric tau protein, indicating a lack of interaction. (<bold>F</bold>) Combined methyl group chemical shift perturbations between free full-length DNAJB1 and DNAJB1 bound to aggregation-prone tau species generated by addition of twofold excess heparin. Binding is observed in the CTDII of DNAJB1. (<bold>G</bold>) Structural representation of DNAJB1 chaperone, with methyl residues showing significant changes upon binding to aggregation-prone tau species highlighted in blue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Mapping DNAJA2 and DNAJB1 chaperone binding to tau species.</title><p>(<bold>A</bold>) <sup>1</sup>H-<sup>15</sup>N TROSY-HSQC of class A J-domain protein Ydj1 (DNAJA2 homolog) residues 111–351 alone (black), and in complex with two molar equivalents of monomeric tau (purple). Residues displaying chemical shift perturbation upon tau binding are indicated. (<bold>B</bold>) <sup>1</sup>H-<sup>15</sup>N TROSY-HSQC of Ydj1<sup>111-351</sup> alone (black), and in complex with two molar equivalents of the aggregation-prone tau species (purple). These tau species were generated by addition of twofold molar excess of heparin to tau. The same amount of heparin was also added to Ydj1<sup>111-351</sup> alone (black). Residues displaying broadening upon interaction with tau are indicated. (<bold>C</bold>) <sup>1</sup>H-<sup>15</sup>N TROSY-HSQC of DNAJA2<sup>256-409</sup> alone (black), and in complex with two molar equivalents of monomeric tau (purple). No changes in the spectrum are observed, indicating that DNAJA2 CTDII and dimerization domains do not interact with the monomeric tau species. (<bold>D</bold>) <sup>1</sup>H-<sup>15</sup>N TROSY-HSQC of DNAJA2<sup>256-409</sup> alone (black), and in complex with two molar equivalents of the aggregation-prone tau species (purple). These tau species were generated by addition of twofold molar excess of heparin to tau. The same amount of heparin was also added to DNAJA2<sup>256-409</sup> alone (black). The presence of chemical shift perturbations confirms that the aggregation-prone tau-heparin species also bind to the CTDII in the presence of the dimerization domain. (<bold>E</bold>) <sup>1</sup>H-<sup>15</sup>N TROSY-HSQC of DNAJB1 CTDs (residues 154–341) alone (black), and upon addition of twofold excess of monomeric tau protein (blue). No changes in chemical shift positions or intensities were detected, indicating lack of binding. (<bold>F</bold>) <sup>1</sup>H-<sup>13</sup>C HMQC spectra of full-length DNAJB1 alone (black), and upon addition of twofold excess of monomeric tau protein (blue). No interaction is visible between the two proteins. (<bold>G</bold>) Same experiment as in (<bold>F</bold>) performed with aggregation-prone (heparin-bound) tau species. Residues displaying significant reduction in intensity upon binding to heparin-tau are indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We then repeated the binding experiment using aggregation-prone tau species, generated by the addition of heparin (<xref ref-type="bibr" rid="bib16">Eschmann et al., 2017</xref>). Interestingly, this tau species, unlike the inert tau monomer, caused significant peak broadening to residues in the second substrate binding region of DNAJA2, located in CTDII (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), whereas only small changes were detected in the CTDI region (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Hence, the DNAJA2 substrate-binding groove in CTDI interacts predominantly with the inert, monomeric tau, while the aggregation-prone tau species preferentially binds to CTDII (<xref ref-type="fig" rid="fig6">Figure 6C, D</xref>). In order to verify that our binding results were not affected by the deletion of the dimerization domain in the DNAJA2(Ydj1)<sup>111-351</sup> construct, we then repeated the binding experiments using a construct comprising only CTDII and the Ydj1 dimerization domains, termed DNAJA2(Ydj1)<sup>256-409</sup>. This DNAJA2 variant, as expected, showed no binding to monomeric tau in our NMR experiments, confirming that tau indeed binds to the CTDI region, which was lacking in this construct (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Addition of heparin-bound tau, however, caused significant CSPs to the spectrum of DNAJA2(Ydj1)<sup>256-409</sup> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>), again confirming the binding of this aggregation-prone tau species to CTDII.</p><p>Having this second, distinct tau-binding domain thus explains both the high affinity of DNAJA2 toward the aggregation-prone tau and the ability of the chaperone to interact with the two tau species.</p><p>We then tested the binding of DNAJB1<sup>154-341</sup> (a dimeric protein lacking the N-terminal JD) to this aggregation-prone tau species. The interaction with tau-heparin, however, caused severe peak broadening, preventing us from obtaining site-specific information. The high molecular mass of the complex formed between multiple aggregation-prone tau monomers and the DNAJB1-dimer is presumably responsible for this effect. To overcome this problem, we utilized a <sup>2</sup>H <sup>13</sup>CH<sub>3</sub>-ILVM sample of full-length DNAJB1 that gave a high-quality <sup>1</sup>H-<sup>13</sup>C HMQC spectrum even upon complex formation with the aggregation-prone tau (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>). Selective peak broadening was detected in methyl residues located in CTDII (<xref ref-type="fig" rid="fig6">Figure 6F, G</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>), indicating that, similarly to DNAJA2 chaperone, the aggregation-prone tau binds to CTDII in DNAJB1. This CTDII site in DNAJB1 was also recently identified as a binding site for another amyloid-forming protein, α-synuclein (<xref ref-type="bibr" rid="bib17">Faust et al., 2020</xref>).</p><p>Hence, DNAJB1 and DNAJA2 recognize seed-competent tau<sup>4R</sup> species predominantly via CTDII, yet the structural differences between the CTDI domains of the chaperones likely cause the diverging specificities for the various tau<sup>4R</sup> species.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Hsp70 chaperones are known to be key factors in tau quality control and turnover (<xref ref-type="bibr" rid="bib42">Miyata et al., 2011</xref>); however, the contributions of their Hsp40 co-chaperones remain poorly understood. In this study, we describe the effects of Hsp40 chaperone family members, DNAJA2 and DNAJB1, on tau amyloid fiber formation in comparison to the well-characterized tau aggregation suppressor HSPB1.</p><p>DNAJA2 chaperone was previously identified as a potent suppressor of tau aggregation (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>). Our results demonstrate that DNAJA2 can interact simultaneously with multiple tau species, which can explain its high effectiveness in aggregation prevention. DNAJA2 does not only bind tau monomers via its CTDI, thus preventing fiber growth by monomer addition, but it also binds aggregation-prone tau species via its CTDII, which effectively reduces the speed of nucleation. Moreover, DNAJA2 even associates with mature tau fibers, which provides an additional pathway for inhibiting the incorporation of new monomers into the growing fibers (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Schematic representation of chaperone-dependent aggregation prevention of tau.</title><p>HSPB1, DNAJA2, and DNAJB1 chaperones play complementary roles in tau aggregation prevention, each affecting different microscopic steps along the tau aggregation pathway and interacting with distinct tau species. HSPB1 chaperone (green) interacts solely with monomeric tau (gray squiggles), preventing its incorporation into the growing fibers. DNAJB1 chaperone (blue) shows a completely distinct tau binding profile – binding only to aggregation-prone tau and to the mature tau fibers, thus inhibiting the formation of nuclei (orange squares), as well as the elongation of existing fibers. Furthermore, DNAJB1, together with the Hsp70 chaperone system, can disaggregate tau fibers, returning the proteins to their soluble monomeric state (<xref ref-type="bibr" rid="bib48">Nachman et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Ferrari et al., 2018</xref>). DNAJA2 (purple) binds to all tau species (monomer, nuclei, and fibers), thus serving as an extremely potent suppressor of tau aggregation. While nuclei and mature fibers selectively interact with a site in the C-terminal domain II (CTDII) of both Hsp40 chaperones, DNAJA2 possesses a second, distinct site in CTDI through which it recognizes the monomeric tau species.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69601-fig7-v2.tif"/></fig><p>Given this multiplicity of interfering pathways, DNAJA2 has the potential to serve as an early protective cellular factor that limits tau aggregation, which explains the correlation between distorted cellular DNAJA2 levels and pathology-linked nucleation sites (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>).</p><p>Remarkably, in comparison to DNAJA2, DNAJB1 displayed significantly different interactions with tau despite the high structural similarity between both chaperones. In fact, unlike DNAJA2, DNAJB1 does not interact with inert tau monomers, although its CTDI is highly homologous to that of the class A chaperone. DNAJB1 affinity, however, is increased by orders of magnitude for the aggregation-prone tau species. There, DNAJB1 also functions as a bona fide chaperone, effectively hindering tau aggregation by preventing the formation of the seeding nuclei, as well as by stably binding to the amyloid fibers themselves, slowing down their growth (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Interestingly, both interactions are mediated by CTDII, thus leaving the CTDI site free to potentially recruit Hsp70 chaperones and initiate the disaggregation of fibers when these are formed.</p><p>This mode of action of DNAJB1 differs significantly from that of the well-characterized tau aggregation-suppressor HSPB1, as well as from the recently described activity of the DNAJC7 chaperone (<xref ref-type="bibr" rid="bib26">Hou et al., 2020</xref>). These chaperones preferentially bind to the PHF6 repeats in inert tau monomers, thus protecting these aggregation-prone regions and preventing them from being incorporated into the growing fibers. By solely interacting with inert tau monomers, though, HSPB1 can only effectively inhibit the rate of fibril elongation, and thus has a limited effect of preventing tau amyloid formation (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><p>In contrast, the actions of DNAJA2 and DNAJB1 result in a significant decrease not only in fibril mass, but also length. This function of the Hsp40 chaperones, compared to HSPB1, could be attributed to their ability to interact with the forming tau fibers, which efficiently blocks the incorporation of additional tau monomers. In addition, the Hsp40 chaperones bind aggregation-prone tau species, thereby blocking their elongation into the mature tau fibers.</p><p>The relatively minor differences in the aggregation-prevention abilities of DNAJB1 and DNAJA2, along with the relatively poor performance of HSPB1 in preventing fibril growth, suggest that, while interaction with soluble tau monomers helps slow aggregation, this does not significantly contribute to the ability of chaperones to prevent amyloid growth once it has begun. It is therefore possible to envision a scenario in which HSPB1 delays amyloid formation during the early stages of tau aggregation via interaction with the monomers, and Hsp40 chaperones later interact with seeds and more mature species to further hinder the fibril formation process.</p><p>One open question is how these chaperones affect the aggregation of tau mutants linked to tauopathies. It has been hypothesized that some variants, such as P301L, may be capable of ‘avoiding’ the chaperone system, thus possibly contributing to the disease pathology. Such behavior was indeed recently observed with the DNAJC7 chaperone, which was found to have a significantly reduced affinity to the tau P301L mutation (<xref ref-type="bibr" rid="bib26">Hou et al., 2020</xref>). Furthermore, in our aggregation-prevention assays, a reduction was observed in the activity of HSPB1 when incubated with the P301L variant compared to wild-type tau (<xref ref-type="bibr" rid="bib43">Mok et al., 2018</xref>; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4B</xref>). For these two chaperones, their reduced efficacy is likely due to the equilibrium of the P301L mutation shifting toward an aggregation-prone seeding conformation of tau (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), for which both DNAJC7 (30) and HSPB1 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) display reduced affinities. In contrast, DNAJA2 and DNAJB1 remained effective in suppressing the aggregation of the P301L variant of tau<sup>4R</sup> (with the anti-aggregation activity of DNAJB1 being even higher for this tauopathy mutant, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4C</xref>), indicating that these Hsp40 chaperones could be effective in suppressing a wide range of tauopathies.</p><p>A second, crucial question that has yet to be answered is whether the reduction of fibril growth by the Hsp40 chaperones, which results in generation of smaller tau fibrils, is indeed beneficial for cellular homeostasis. A recent study showed that the disaggregation of tau by the DNAJB1/Hsp70/Hsp110 chaperones generates low-molecular-weight tau species, which were seeding-competent in cell culture models (<xref ref-type="bibr" rid="bib48">Nachman et al., 2020</xref>). Hence, chaperone-mediated tau disaggregation may not be beneficial per se, but may instead be involved in the prion-like propagation of tau pathology. The smaller tau species generated during the DNAJA2 and DNAJB1 aggregation-prevention processes could then have similar prion-like propagation properties, acting as seeds that can sequester more tau protein into amyloid aggregates. In such a case, chaperone-mediated aggregation prevention would, in fact, accelerate the progression of disease, ultimately proving detrimental to cell health. HSPB1 chaperones, on the other hand, do not generate smaller tau species during their aggregation prevention and could therefore be more beneficial in slowing the progression of disease, despite their lower chaperoning activity.</p><p>However, another important aspect to consider is that aggregation prevention in the cell does not occur in isolation and can also be coupled to protein degradation via the proteasome or autophagy. These pathways could potentially be more potent in degrading smaller tau fibrils and aggregation-prone monomers than the mature fibrils, thereby rendering the activity of DNAJA2 and DNAJB1 beneficial overall.</p><p>Hence, further studies will be required to understand the full role of Hsp40-mediated tau aggregation prevention in the cell, as well as to evaluate the therapeutic potential of the Hsp40 chaperone machineries in combating tauopathies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Construct preparation</title><p>Tau<sup>4R</sup> (residues 244–372, C322A) wt and mutants, HSPB1 (S15D, S78D, S82D, I181G, V183G), DNAJA2, and DNAJB1 (residues 154–341) were expressed in <italic>Escherichia coli</italic> BL21 (DE3) cells from pET-29b(+) vector with a N-terminal His<sub>6</sub> tag followed by a tobacco etch virus (TEV) protease cleavage site. Tau (C322S), DNAJB1, and Ydj1 (yeast orthologue of DNAJA) constructs were expressed from the pET-SUMO vector with an N-terminal His<sub>6</sub> purification tag and a Ulp1 cleavage site (DNAJB1 plasmid was a gift from B. Bukau, University of Heidelberg).</p></sec><sec id="s4-2"><title>Protein expression</title><p>Cells were grown in Luria Bertani broth (LB) to OD<sub>600 </sub>≈ 0.8 at 37°C, and expression was induced by addition of 1 mM isopropyl-β-D-thiogalactoside (IPTG). Cells expressing HSPB1, DNAJA2, and DNAJB1 chaperone variants were allowed to proceed overnight at 25°C and cells expressing tau constructs at 18°C.</p><p>Isotopically labeled tau and tau<sup>4R</sup> proteins for NMR were grown in M9 H<sub>2</sub>O media supplemented with <sup>15</sup>NH<sub>4</sub>Cl (and <sup>13</sup>C-glucose) as the sole nitrogen (and carbon) source. Protein expression was induced with 1 mM IPTG at 18°C overnight.</p><p>Labeled DNAJB1<sup>154-341</sup>, Ydj1<sup>111-351</sup>, and Ydj1<sup>256-409</sup> were grown at 37°C in M9 D<sub>2</sub>O media supplemented with [<sup>2</sup>H,<sup>12</sup>C]-glucose and <sup>15</sup>NH<sub>4</sub>Cl as the sole source of carbon and nitrogen. In the case of DNAJB1, 2-ketobutyric acid-<sup>13</sup>C<sub>4</sub>,3,3-d<sub>2</sub> sodium salt (60 mg/L), 2-ketoisovaleric acid-<sup>13</sup>C<sub>4</sub>,d<sub>3</sub> sodium salt (80 mg/L), and <sup>13</sup>C-L-methionine (100 mg/L) (Cambridge Isotope Laboratories) were added 1 hr prior to induction with 1 mM IPTG, following the procedure of <xref ref-type="bibr" rid="bib64">Tugarinov et al., 2006</xref> to produce U-<sup>2</sup>H, <sup>15</sup>N, <sup>13</sup>CH<sub>3</sub>-ILVM labeled protein. Proteins were expressed at 25°C overnight.</p></sec><sec id="s4-3"><title>Purification of labeled and unlabeled proteins</title><p>Proteins were purified on a Ni-NTA HiTrap HP column (GE Life Sciences). The purification tag was cleaved by the appropriate protease (see Construct preparation), and the cleaved protein was further separated from the uncleaved protein, the tag, and the protease on a Ni-NTA HiTrap HP column. HSPB1, DNAJA2, and DNAJB1 chaperone variants were concentrated on an Amicon Ultra-15 10K molecular weight cutoff (MWCO) filter (Millipore) and further purified on a HiLoad 16/600 Superdex 200 pg gel filtration column (GE Healthcare), equilibrated with 25 mM HEPES pH 7.0, 150 mM KCl, and 2 mM DTT. Tau constructs were concentrated on an Amicon Ultra-15 3.5K MWCO filter (Millipore) and further purified on a HiLoad 16/600 Superdex 75 pg gel filtration column (GE Healthcare) equilibrated with 25 mM HEPES pH 7.0, 300 mM KCl, and 2 mM DTT. Purity of proteins was confirmed by SDS-PAGE.</p></sec><sec id="s4-4"><title>Aggregation-prevention assays</title><p>Aggregation kinetics were measured in Synergy H1 microplate reader (BioTek) in black, flat-bottom, 96-well plates (Nunc). Tau or tau<sup>4R</sup> variants (10 μM) were pre-incubated in the presence or absence of indicated chaperones for 10 min at 37°C. All proteins in the assay were buffer exchanged into the assay buffer (50 mM HEPES pH 7.4, 50 mM KCl, and 2 mM DTT). ThT (Sigma) at a final concentration of 10 μM was added, and the aggregation was induced by the addition of 2.5 μM freshly prepared heparin salt solution (Sigma). Aggregation reactions were run at 37°C with continuous shaking (567 rpm) and monitored by ThT fluorescence (excitation = 440 nm, emission = 485 nm, bandwidth), using an area scan mode with a 3 × 3 matrix for each well. Black, flat-bottom, 96-well plates (Nunc) sealed with optical adhesive film (Applied Biosystems) were used. For data processing, baseline curves at same conditions but without heparin were subtracted from the data. Samples were run in triplicate, and the experiments were repeated at least four times with similar results.</p></sec><sec id="s4-5"><title>Seeded tau aggregation reactions</title><p>Tau seeds were prepared from mature tau fibers generated under similar conditions to these in the aggregation-prevention assays, except that ThT was omitted. The fibers were then sonicated using a probe sonicator (Vibra-Cell, SONICS) with an amplitude of 40%, for 30 s on and 10 s off, for a total of 7 min. The sonicated fibers were immediately added to monomeric tau, ThT, and DTT in a 96-well plate in the ratios described above and ThT fluorescence was measured as a function of time.</p></sec><sec id="s4-6"><title>Dynamic light scattering (DLS)</title><p>The hydrodynamic radius of tau<sup>4R</sup> seeds was measured by DLS on a DynaPro DLS Plate Reader III (Wyatt Technology). Tau seeds (10 µM) were loaded on a 96-well black, clear-bottom plates (Nunc), and subjected to a 5 min 3000 × g centrifugation to remove air bubbles from the wells. Measurements were carried out 20 times per well before averaging, with 5 s acquisitions at 25°C. Resulting autocorrelation functions were fitted with the equation<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi/><mml:msup><mml:mrow><mml:mi>β</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mi mathvariant="normal">D</mml:mi><mml:msup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>τ</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula>where <inline-formula><mml:math id="inf1"><mml:mi>β</mml:mi></mml:math></inline-formula> is the coherence factor, D is the translational diffusion coefficient, and q is the scattering wave vector given by<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mi>q</mml:mi><mml:mo>=</mml:mo><mml:mi/><mml:mfrac><mml:mrow><mml:mn>4</mml:mn><mml:mi>π</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mo>⁡</mml:mo><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:math></disp-formula>where n is the solvent refractive index (n = 1.334 was used), <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mi/></mml:mrow></mml:msub></mml:math></inline-formula> is the wavelength used by the instrument, and <inline-formula><mml:math id="inf3"><mml:mi>θ</mml:mi></mml:math></inline-formula> is the scattering angle.</p><p>The Stokes radius (<italic>R<sub>s</sub></italic>) was calculated from the translational diffusion coefficient, <italic>D,</italic> using the Stokes–Einstein equation<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mi/><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn><mml:mi>π</mml:mi><mml:mi>η</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>where k<sub>B</sub> is Boltzmann coefficient <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1.38</mml:mn><mml:mo>⋅</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>23</mml:mn></mml:mrow></mml:msup><mml:mfrac><mml:mrow><mml:mi>k</mml:mi><mml:mi>g</mml:mi><mml:msup><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>K</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> T is the temperature (298 K), and <inline-formula><mml:math id="inf5"><mml:mi>η</mml:mi></mml:math></inline-formula> is the dynamic viscosity of our buffer.</p></sec><sec id="s4-7"><title>Aggregation-prevention data fitting</title><p>All aggregation kinetics were fitted with a saturation-elongation-fragmentation model (<xref ref-type="bibr" rid="bib40">Meisl et al., 2016</xref>) using a critical nucleus size of <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>. The differential equation system for this model is<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>P</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mi>m</mml:mi><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>M</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf7"><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is the number concentration of fibrils, <inline-formula><mml:math id="inf8"><mml:mi>M</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is the mass concentration of a fibril, <inline-formula><mml:math id="inf9"><mml:mi>m</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is the monomer concentration, <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the nucleation rate, <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the fragmentation rate, <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the elongation rate, and <inline-formula><mml:math id="inf13"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the equilibrium constant for monomer addition to an existing fibril. The effect of heparin was not included explicitly in this model and is implicitly contained in the kinetic rates. For fitting, the ThT fluorescence signal <inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> of the ith time trace was converted to the mass concentration of the fibrils <inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> according to<disp-formula id="equ6"><label>(5)</label><mml:math id="m6"><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Here, <inline-formula><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the highest tau<sup>4R</sup> concentration used in the experiments and <inline-formula><mml:math id="inf17"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> is the ThT signal of the long-term plateau for the time trace with the highest tau<sup>4R</sup> concentration. The resulting mass concentration <inline-formula><mml:math id="inf18"><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> was then fitted by numerically solving the differential equation system <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> for <inline-formula><mml:math id="inf19"><mml:mi>M</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula>, using the initial conditions <inline-formula><mml:math id="inf20"><mml:mi>M</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="inf21"><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, and <inline-formula><mml:math id="inf22"><mml:mi>m</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, where <inline-formula><mml:math id="inf23"><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the initial concentration of tau<sup>4R</sup> monomers for the ith time trace. Prior to fitting, the time traces <inline-formula><mml:math id="inf24"><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> were smoothed by binning data points to reduce noise and to speed up fitting. The bin size was 2–5 data points. Fitting was performed using the 'differential evolution' method (<xref ref-type="bibr" rid="bib62">Storn and Price, 1997</xref>) in Mathematica 11.2 (Wolfram). Importantly, <inline-formula><mml:math id="inf25"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> cannot be independently obtained from unseeded data. We therefore arbitrarily set <inline-formula><mml:math id="inf26"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula> for the global fit of the unseeded data at all monomer concentrations, thus obtaining <inline-formula><mml:math id="inf27"><mml:msub><mml:mrow><mml:mi>k</mml:mi><mml:mi>'</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf28"><mml:msub><mml:mrow><mml:mi>k</mml:mi><mml:mi>'</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. In a second step, we determined <inline-formula><mml:math id="inf29"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf30"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf31"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> in a global fit of a data set including aggregation seeds using<disp-formula id="equ7"><label>(6)</label><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>P</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mo>′</mml:mo></mml:msubsup><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mi>M</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>M</mml:mi><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>E</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>with the initial conditions <inline-formula><mml:math id="inf32"><mml:mi>M</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf33"><mml:mi>P</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="inf34"><mml:mi>m</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn><mml:mi/><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:math></inline-formula>. Here, <inline-formula><mml:math id="inf35"><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the mass concentration of the seeds and <inline-formula><mml:math id="inf36"><mml:mi>L</mml:mi></mml:math></inline-formula> is the length of the seeds. We determined <inline-formula><mml:math id="inf37"><mml:mi>L</mml:mi></mml:math></inline-formula> by measuring the Stokes radius <inline-formula><mml:math id="inf38"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>55</mml:mn><mml:mi/><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:math></inline-formula> of the seeds using DLS (see above). We then modeled the seeds as an ellipsoid with a long axis <inline-formula><mml:math id="inf39"><mml:mi>a</mml:mi></mml:math></inline-formula> (seed length) and a short axis <inline-formula><mml:math id="inf40"><mml:mi>b</mml:mi></mml:math></inline-formula> (fibril thickness). The friction coefficient for an ellipsoid is given by <inline-formula><mml:math id="inf41"><mml:msub><mml:mrow><mml:mi>ξ</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mn>6</mml:mn><mml:mi>π</mml:mi><mml:mi>η</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>, which must be identical to that of a sphere with the Stokes radius <inline-formula><mml:math id="inf42"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> given by <inline-formula><mml:math id="inf43"><mml:msub><mml:mrow><mml:mi>ξ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mi>π</mml:mi><mml:mi>η</mml:mi><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. From the equality, the fibril length <inline-formula><mml:math id="inf44"><mml:mi>a</mml:mi></mml:math></inline-formula> can be determined given that the fibril thickness <inline-formula><mml:math id="inf45"><mml:mi>b</mml:mi></mml:math></inline-formula> is known. Based on existing cryo-EM structures of tau-fibrils (6QJH, 6QJM, 6QJP), we estimated <inline-formula><mml:math id="inf46"><mml:mi>b</mml:mi><mml:mo>~</mml:mo><mml:mn>10</mml:mn><mml:mi/><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:math></inline-formula>, which results in <inline-formula><mml:math id="inf47"><mml:mi>a</mml:mi><mml:mo>~</mml:mo><mml:mn>200</mml:mn><mml:mi/><mml:mi>n</mml:mi><mml:mi>m</mml:mi></mml:math></inline-formula>. Given the spacing of tau monomers in a fibril of approximately 2 nm, we estimated a seed length of <inline-formula><mml:math id="inf48"><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn></mml:math></inline-formula> tau monomers. Error estimates of the kinetic rates were obtained by fitting two independent data sets.</p><p>Fitting of the data in the presence of chaperones was performed for each kinetic trace individually by fixing the kinetic rates to those determined in the absence of chaperone and only allowing one rate to vary at a time. An exception was the data set for DNAJA2 in which we performed a simultaneous global fit of seeded and unseeded experimental traces (<xref ref-type="disp-formula" rid="equ4 equ6 equ7">Equations 4–6</xref>) to identify the simultaneous effect of DNAJA2 on <inline-formula><mml:math id="inf49"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf50"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf51"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. For all fits in which only a single parameter was scanned, we used 'simulated annealing' to optimize the parameters. We would like to note that the amplitude of the aggregation kinetics was not a free-fitting parameter but was determined by the total concentration of tau<sup>4R</sup> monomers (10 μM) in the experiment. Hence, fitting of the aggregation kinetics in the presence of chaperones assumes that the presence of chaperone does not alter the ThT concentration accessible in solution to stain the fibrils.</p></sec><sec id="s4-8"><title>NMR spectroscopy</title><p>All NMR experiments were carried out at 25°C on 14.1 T (600 MHz), 18.8T (800 MHz), or 23.5 T (1000 MHz) Bruker spectrometers equipped with triple resonance single (z) or triple (x, y, z) gradient cryoprobes. The experiments were processed with NMRPipe (<xref ref-type="bibr" rid="bib14">Delaglio et al., 1995</xref>) and analyzed with NMRFAM-SPARKY (<xref ref-type="bibr" rid="bib22">Goddard and Kneller, 2000</xref>) and CCPN (<xref ref-type="bibr" rid="bib67">Vranken et al., 2005</xref>).</p></sec><sec id="s4-9"><title>NMR assignment experiments</title><p>Assignments for tau<sup>4R</sup> were transferred from the BMRB (entry 19253) and corroborated by HNCACB, CBCA(CO)NH, HN(CA)CO, and HNCO experiments on a 4 mM sample of [U- <sup>15</sup>N,<sup>13</sup>C]-labeled tau<sup>4R</sup> in 50 mM HEPES pH 7.4, 50 mM KCl, 1 mM DTT, 0.03% NaN<sub>3</sub>, and 10% D<sub>2</sub>O. The assignment experiments were recorded on an 800 MHz magnet, resulting in the unambiguous assignment of 90% of non-proline residues.</p><p>Tau-heparin complex assignments were obtained by recording 3D HNCA, CBCA(CO)NH, and HN(CA)CO on a 2.5 mM [U-<sup>13</sup>C,<sup>15</sup>N]-labeled tau<sup>4R</sup> sample supplemented with 2.5 mM heparin. The experiments were recorded on an 800 MHz magnet and 88% of non-proline residues were assigned.</p></sec><sec id="s4-10"><title>Secondary structure propensities</title><p>Secondary structure propensities for tau<sup>4R</sup> and tau<sup>4R</sup>-heparin complex were calculated from backbone C′, C<sub>α</sub>, and C<sub>β</sub>, <sup>1</sup>H, <sup>15</sup>N chemical shifts following a procedure described in <xref ref-type="bibr" rid="bib39">Marsh et al., 2006</xref>. Proline and cysteine residues were omitted from this calculation.</p></sec><sec id="s4-11"><title>Residual dipolar couplings (RDCs)</title><p>Backbone amide <sup>1</sup>D<sub>NH </sub>RDCs were measured using a 300 μM sample of tau<sup>4R</sup>, tau P301L, or tau P301S diluted in 50 mM HEPES pH 7.4 buffer with 100 mM KCl. The one-bond N-H RDCs were determined by using inphase-antiphase (IPAP)-HSQC experiments (<xref ref-type="bibr" rid="bib49">Ottiger et al., 1998</xref>), and <sup>1</sup>D<sub>NH</sub> values were calculated as the difference between splittings measured in the isotropic phase and in a sample in which tau<sup>4R</sup>, tau<sup>4R</sup> P301S, or tau<sup>4R</sup> P301L had been aligned in 5 mg/mL Pf1 bacteriophage (Asla) or in 4.5% (vov/vol) C12E5/n-hexanol alignment medium (Sigma). The experiments were recorded on a 1000 MHz Bruker spectrometer and RDCs ranged from +20 to −10 Hz. The heparin-bound tau sample (1:1 tau:heparin molar ratio) was only aligned in 16 mg/mL bacteriophage pf1 and the measured RDCs ranged from +9 to −7 Hz.</p></sec><sec id="s4-12"><title>NMR tau-chaperone binding experiments</title><p>Tau interaction with chaperones was assayed for 200 µM samples of [U-<sup>15</sup>N]-labeled tau, tau<sup>4R</sup>, or tau<sup>4R</sup> P301S and P301L mutants. Tau variants were measured alone or upon addition of heparin (200 µM) and/or chaperones (100 or 400 µM; as indicated in spectrum) in 50 mM HEPES pH 7.0, 50 mM KCl, 1 mM DTT, 0.03% NaN<sub>3</sub>, and 10% D<sub>2</sub>O. <sup>1</sup>H-<sup>15</sup>N HSQC-TROSY spectra were acquired for each sample, and peak intensities were determined by quantifying peak volumes. Regions of tau<sup>4R</sup> with signal loss greater than one standard deviation from the average intensity ratio were determined to be the regions of binding.</p><p>High salt binding experiments were performed with samples of <sup>15</sup>N-tau<sup>4R</sup> (200 µM) and 400 µM [U-<sup>1</sup>H]-labeled chaperones in 50 mM HEPES pH 7.0, 300 mM KCl, 1 mM DTT, 0.03% NaN<sub>3</sub>, and 10% D<sub>2</sub>O. Binding was determined by calculating intensity ratios as described above.</p><p>The binding of DNAJB1 and DNAJA2 chaperones to tau<sup>4R</sup> was measured by acquiring <sup>1</sup>H-<sup>15</sup>N HSQC-TROSY spectra for 200 μM [U- <sup>2</sup>H,<sup>15</sup>N]-labeled DNAJB1<sup>154-341</sup> or Ydj1<sup>111-351</sup> alone or with twofold excess of deuterated tau<sup>4R</sup>. The reactions were measured in 50 mM HEPES pH 7.0, 50 mM KCl, 1 mM DTT, 0.03% NaN<sub>3</sub>, and 10% D<sub>2</sub>O. Backbone DNAJB1<sup>154-341</sup> and Ydj1<sup>111-351</sup> assignments were available through the BMRB (entries 27998 and 28000, respectively).</p><p>The interaction of full-length DNAJB1 to tau<sup>4R</sup> was determined by acquiring <sup>1</sup>H-<sup>13</sup>C HMQC methyl-TROSY spectra (<xref ref-type="bibr" rid="bib63">Tugarinov et al., 2003</xref>) for 100 μM [<sup>2</sup>H, <sup>13</sup>CH<sub>3</sub>]-ILVM-labeled DNAJB1 alone or with 200 μM <sup>2</sup>H-tau<sup>4R</sup> (or tau-heparin complex) in 50 mM HEPES pH 7.4, 100 mM KCl, 2 mM DTT and 0.03% NaN<sub>3</sub> in 100% D<sub>2</sub>O. ILVM assignments for full-length DNAJB1 were taken from previous work in our lab (<xref ref-type="bibr" rid="bib17">Faust et al., 2020</xref>). Binding regions were determined by intensity ratio as described above.</p></sec><sec id="s4-13"><title>NMR chemical shift perturbations</title><p>The interaction of tau<sup>4R</sup> with heparin was monitored by 2D <sup>1</sup>H–<sup>15</sup>N HSQC experiments. Heparin (40–400 μM) was titrated into 200 μM of <sup>15</sup>N-labeled tau<sup>4R</sup> in 50 mM HEPES pH 7.0, 50 mM KCl, 1 mM DTT, 0.03% NaN<sub>3</sub>, and 10% D<sub>2</sub>O and chemical shifts were recorded.</p><p>CSPs were calculated from the relation<disp-formula id="equ9"><label>(7)</label><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>δ</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mi mathvariant="normal">Δ</mml:mi><mml:msubsup><mml:mi>δ</mml:mi><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/></mml:msubsup><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msqrt><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>5</mml:mn></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:math></disp-formula>where Δδ<sub>H</sub> is the amide proton chemical shift difference, and Δδ<sub>N</sub> is the <sup>15</sup>N backbone chemical shift difference. CSPs greater than one standard deviation from the mean were considered significant.</p></sec><sec id="s4-14"><title>Negative stain electron microscopy</title><p>Tau fibrils or tau fibrils-chaperone mixtures (10 µl) were deposited on glow-discharged carbon-coated copper EM grids (Electron Microscopy Sciences), washed with three consecutive drops of 1% w/v Uranyl-formate, and air-dried. Imaging was performed on an FEI T12 Spirit transmission electron microscope at 120 kV and a magnification of 9300–30,000 times, equipped with a Gatan OneView CMOS 4K × 4K CCD camera.</p></sec><sec id="s4-15"><title>Chaperone-fibril co-sedimentation assay</title><p>Preformed tau<sup>4R</sup> fibers (10 μM) were incubated with HSPB1, DNAJB1, and DNAJA2 chaperones (10 μM) for 20 min at 37°C in 50 mM HEPES pH 7.4 and 50 mM KCl. Tau fibers were separated from the unbound chaperones by centrifugation at 16,900 g for 30 min. The pellets were washed, resuspended in 50 μL of buffer with 20% SDS, and sonicated for 10 min. Samples were incubated for 5 min at 95°C and run on a 4–20% gradient SDS-PAGE gel (GenScript).</p></sec><sec id="s4-16"><title>Fluorescence anisotropy measurements</title><p>Steady-state equilibrium binding of DNAJA2, DNAJB1 chaperones to preformed tau fibers was measured by fluorescence polarization using 100 nM of fluorescently tagged chaperones (DNAJB1 G194C-AF488 or DNAJA2-AF488).</p><p>Steady-state equilibrium binding of DNAJB1, DNAJA2, and HSPB1 to monomeric tau was measured by fluorescence anisotropy using 100 nM of fluorescently tagged tau (tau C291S, C322S, L243C-AF488). Samples were allowed to equilibrate for 10 min at 37°C, and measurements were performed on a Tecan SPARK 10M plate reader in black, flat-bottomed 384 square well plates. The excitation filter was centered on 485 nm with a bandwidth of 20 nm, and the emission filter was centered on 535 nm with a bandwidth of 25 nm. The gain and Z position were optimized from a well in the center of the binding curve, followed by calibration of the G factor. 60 flashes were performed per well.</p><p>Data were fit to a one-site binding model using OriginPro version 2018.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>RR is supported by the European Research Council starting grant (ERC-2018-STG 802001), Abisch Frenkel Foundation for the Promotion of Life Sciences, and a research grant from the Blythe Brenden-Mann New Scientist Fund. The electron microscopy studies were partially supported by the Irving and Cherna Moskowitz Center for Nano and BioNano Imaging (Weizmann Institute of Science). We thank Eran Ofek for fruitful discussions and advice.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Formal analysis, Validation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Formal analysis, Supervision, Validation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-69601-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files are provided for Figures 1, 2, 3, and 4 including the full raw unedited gel in figure 2A.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abisambra</surname> <given-names>JF</given-names></name><name><surname>Jinwal</surname> <given-names>UK</given-names></name><name><surname>Suntharalingam</surname> <given-names>A</given-names></name><name><surname>Arulselvam</surname> <given-names>K</given-names></name><name><surname>Brady</surname> <given-names>S</given-names></name><name><surname>Cockman</surname> <given-names>M</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau</article-title><source>Journal of Molecular Biology</source><volume>421</volume><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.02.003</pub-id><pub-id pub-id-type="pmid">22343013</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala Mariscal</surname> <given-names>SM</given-names></name><name><surname>Kirstein</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>J-domain proteins interaction with neurodegenerative disease-related proteins</article-title><source>Experimental Cell Research</source><volume>399</volume><elocation-id>112491</elocation-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2021.112491</pub-id><pub-id pub-id-type="pmid">33460589</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballatore</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>VM-Y</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tau-mediated neurodegeneration in Alzheimer's disease and related disorders</article-title><source>Nature Reviews Neuroscience</source><volume>8</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/nrn2194</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barghorn</surname> <given-names>S</given-names></name><name><surname>Davies</surname> <given-names>P</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain</article-title><source>Biochemistry</source><volume>43</volume><fpage>1694</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1021/bi0357006</pub-id><pub-id pub-id-type="pmid">14769047</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname> <given-names>HER</given-names></name><name><surname>Clouser</surname> <given-names>AF</given-names></name><name><surname>Klevit</surname> <given-names>RE</given-names></name><name><surname>Nath</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HspB1 and Hsc70 chaperones engage distinct tau species and have different inhibitory effects on amyloid formation</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>2687</fpage><lpage>2700</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.803411</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biancalana</surname> <given-names>M</given-names></name><name><surname>Koide</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular mechanism of Thioflavin-T binding to amyloid fibrils</article-title><source>Biochimica Et Biophysica Acta (BBA) - Proteins and Proteomics</source><volume>1804</volume><fpage>1405</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2010.04.001</pub-id><pub-id pub-id-type="pmid">20399286</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Mandelkow</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains</article-title><source>Molecular Biology of the Cell</source><volume>10</volume><fpage>727</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1091/mbc.10.3.727</pub-id><pub-id pub-id-type="pmid">10069814</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brehme</surname> <given-names>M</given-names></name><name><surname>Voisine</surname> <given-names>C</given-names></name><name><surname>Rolland</surname> <given-names>T</given-names></name><name><surname>Wachi</surname> <given-names>S</given-names></name><name><surname>Soper</surname> <given-names>JH</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Orton</surname> <given-names>K</given-names></name><name><surname>Villella</surname> <given-names>A</given-names></name><name><surname>Garza</surname> <given-names>D</given-names></name><name><surname>Vidal</surname> <given-names>M</given-names></name><name><surname>Ge</surname> <given-names>H</given-names></name><name><surname>Morimoto</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease</article-title><source>Cell Reports</source><volume>9</volume><fpage>1135</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.09.042</pub-id><pub-id pub-id-type="pmid">25437566</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunello</surname> <given-names>CA</given-names></name><name><surname>Merezhko</surname> <given-names>M</given-names></name><name><surname>Uronen</surname> <given-names>R-L</given-names></name><name><surname>Huttunen</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms of secretion and spreading of pathological tau protein</article-title><source>Cellular and Molecular Life Sciences</source><volume>77</volume><fpage>1721</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03349-1</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname> <given-names>B</given-names></name><name><surname>Bourdenx</surname> <given-names>M</given-names></name><name><surname>Luengo</surname> <given-names>E</given-names></name><name><surname>Diaz</surname> <given-names>A</given-names></name><name><surname>Sohn</surname> <given-names>PD</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Juste</surname> <given-names>YR</given-names></name><name><surname>Wegmann</surname> <given-names>S</given-names></name><name><surname>Patel</surname> <given-names>B</given-names></name><name><surname>Young</surname> <given-names>ZT</given-names></name><name><surname>Kuo</surname> <given-names>SY</given-names></name><name><surname>Rodriguez-Navarro</surname> <given-names>JA</given-names></name><name><surname>Shao</surname> <given-names>H</given-names></name><name><surname>Lopez</surname> <given-names>MG</given-names></name><name><surname>Karch</surname> <given-names>CM</given-names></name><name><surname>Goate</surname> <given-names>AM</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Hyman</surname> <given-names>BT</given-names></name><name><surname>Gan</surname> <given-names>L</given-names></name><name><surname>Cuervo</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2238</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22501-9</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Drombosky</surname> <given-names>KW</given-names></name><name><surname>Hou</surname> <given-names>Z</given-names></name><name><surname>Sari</surname> <given-names>L</given-names></name><name><surname>Kashmer</surname> <given-names>OM</given-names></name><name><surname>Ryder</surname> <given-names>BD</given-names></name><name><surname>Perez</surname> <given-names>VA</given-names></name><name><surname>Woodard</surname> <given-names>DR</given-names></name><name><surname>Lin</surname> <given-names>MM</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name><name><surname>Joachimiak</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tau local structure shields an amyloid-forming motif and controls aggregation propensity</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2493</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10355-1</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname> <given-names>C</given-names></name><name><surname>Stankowski</surname> <given-names>JN</given-names></name><name><surname>Carlomagno</surname> <given-names>Y</given-names></name><name><surname>Stetler</surname> <given-names>C</given-names></name><name><surname>Petrucelli</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Acetylation: a new key to unlock tau’s role in neurodegeneration</article-title><source>Alzheimer's Research &amp; Therapy</source><volume>6</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1186/alzrt259</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabir</surname> <given-names>DV</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>Richter-Landsberg</surname> <given-names>C</given-names></name><name><surname>Lee</surname> <given-names>VM</given-names></name><name><surname>Forman</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology</article-title><source>The American Journal of Pathology</source><volume>164</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63106-9</pub-id><pub-id pub-id-type="pmid">14695329</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaglio</surname> <given-names>F</given-names></name><name><surname>Grzesiek</surname> <given-names>S</given-names></name><name><surname>Vuister</surname> <given-names>G</given-names></name><name><surname>Zhu</surname> <given-names>G</given-names></name><name><surname>Pfeifer</surname> <given-names>J</given-names></name><name><surname>Bax</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>NMRPipe: A multidimensional spectral processing system based on UNIX pipes</article-title><source>Journal of Biomolecular NMR</source><volume>6</volume><fpage>277</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/BF00197809</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dou</surname> <given-names>F</given-names></name><name><surname>Netzer</surname> <given-names>WJ</given-names></name><name><surname>Tanemura</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Hartl</surname> <given-names>FU</given-names></name><name><surname>Takashima</surname> <given-names>A</given-names></name><name><surname>Gouras</surname> <given-names>GK</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Chaperones increase association of tau protein with microtubules</article-title><source>PNAS</source><volume>100</volume><fpage>721</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1073/pnas.242720499</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschmann</surname> <given-names>NA</given-names></name><name><surname>Georgieva</surname> <given-names>ER</given-names></name><name><surname>Ganguly</surname> <given-names>P</given-names></name><name><surname>Borbat</surname> <given-names>PP</given-names></name><name><surname>Rappaport</surname> <given-names>MD</given-names></name><name><surname>Akdogan</surname> <given-names>Y</given-names></name><name><surname>Freed</surname> <given-names>JH</given-names></name><name><surname>Shea</surname> <given-names>J-E</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Signature of an aggregation-prone conformation of tau</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>44739</elocation-id><pub-id pub-id-type="doi">10.1038/srep44739</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faust</surname> <given-names>O</given-names></name><name><surname>Abayev-Avraham</surname> <given-names>M</given-names></name><name><surname>Wentink</surname> <given-names>AS</given-names></name><name><surname>Maurer</surname> <given-names>M</given-names></name><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>London</surname> <given-names>N</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name><name><surname>Rosenzweig</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HSP40 proteins use class-specific regulation to drive HSP70 functional diversity</article-title><source>Nature</source><volume>587</volume><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2906-4</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ferrari</surname> <given-names>LGW</given-names></name><name><surname>Wezel</surname> <given-names>M</given-names></name><name><surname>Kos</surname> <given-names>R</given-names></name><name><surname>Konstantoulea</surname> <given-names>A</given-names></name><name><surname>Bezouwen</surname> <given-names>LS</given-names></name><name><surname>Förster</surname> <given-names>FG</given-names></name><name><surname>Rüdiger</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human chaperones untangle fibrils of the alzheimer protein tau</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/426650</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname> <given-names>AWP</given-names></name><name><surname>Falcon</surname> <given-names>B</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Murzin</surname> <given-names>AG</given-names></name><name><surname>Murshudov</surname> <given-names>G</given-names></name><name><surname>Garringer</surname> <given-names>HJ</given-names></name><name><surname>Crowther</surname> <given-names>RA</given-names></name><name><surname>Ghetti</surname> <given-names>B</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name><name><surname>Scheres</surname> <given-names>SHW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cryo-EM structures of tau filaments from Alzheimer’s disease</article-title><source>Nature</source><volume>547</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature23002</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontaine</surname> <given-names>SN</given-names></name><name><surname>Martin</surname> <given-names>MD</given-names></name><name><surname>Akoury</surname> <given-names>E</given-names></name><name><surname>Assimon</surname> <given-names>VA</given-names></name><name><surname>Borysov</surname> <given-names>S</given-names></name><name><surname>Nordhues</surname> <given-names>BA</given-names></name><name><surname>Sabbagh</surname> <given-names>JJ</given-names></name><name><surname>Cockman</surname> <given-names>M</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>3971</fpage><lpage>3981</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv135</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freilich</surname> <given-names>R</given-names></name><name><surname>Betegon</surname> <given-names>M</given-names></name><name><surname>Tse</surname> <given-names>E</given-names></name><name><surname>Mok</surname> <given-names>S-A</given-names></name><name><surname>Julien</surname> <given-names>O</given-names></name><name><surname>Agard</surname> <given-names>DA</given-names></name><name><surname>Southworth</surname> <given-names>DR</given-names></name><name><surname>Takeuchi</surname> <given-names>K</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Competing protein-protein interactions regulate binding of Hsp27 to its client protein tau</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4563</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07012-4</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Kneller</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2000">2000</year><source>SPARKY 3</source><publisher-loc>San Francisco</publisher-loc><publisher-name>University of California</publisher-name></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustke</surname> <given-names>N</given-names></name><name><surname>Trinczek</surname> <given-names>B</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Mandelkow</surname> <given-names>EM</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Domains of tau protein and interactions with microtubules</article-title><source>Biochemistry</source><volume>33</volume><fpage>9511</fpage><lpage>9522</lpage><pub-id pub-id-type="doi">10.1021/bi00198a017</pub-id><pub-id pub-id-type="pmid">8068626</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanger</surname> <given-names>DP</given-names></name><name><surname>Anderton</surname> <given-names>BH</given-names></name><name><surname>Noble</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tau phosphorylation: the therapeutic challenge for neurodegenerative disease</article-title><source>Trends in Molecular Medicine</source><volume>15</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2009.01.003</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname> <given-names>MR</given-names></name><name><surname>Mueller</surname> <given-names>L</given-names></name><name><surname>Pardi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions</article-title><source>Nature Structural Biology</source><volume>5</volume><fpage>1065</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1038/4176</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hou</surname> <given-names>Z</given-names></name><name><surname>Wydorski</surname> <given-names>PM</given-names></name><name><surname>Perez</surname> <given-names>VA</given-names></name><name><surname>Mendoza-Oliva</surname> <given-names>A</given-names></name><name><surname>Ryder</surname> <given-names>BD</given-names></name><name><surname>Mirbaha</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DnaJC7 binds natively folded structural elements in tau to inhibit amyloid formation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.12.15.422895</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Rossi</surname> <given-names>P</given-names></name><name><surname>Kalodimos</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural basis for client recognition and activity of Hsp40 chaperones</article-title><source>Science</source><volume>365</volume><fpage>1313</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1126/science.aax1280</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinwal</surname> <given-names>UK</given-names></name><name><surname>Akoury</surname> <given-names>E</given-names></name><name><surname>Abisambra</surname> <given-names>JF</given-names></name><name><surname>O'Leary</surname> <given-names>JC</given-names></name><name><surname>Thompson</surname> <given-names>AD</given-names></name><name><surname>Blair</surname> <given-names>LJ</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Bacon</surname> <given-names>J</given-names></name><name><surname>Nordhues</surname> <given-names>BA</given-names></name><name><surname>Cockman</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Borysov</surname> <given-names>S</given-names></name><name><surname>Uversky</surname> <given-names>VN</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Imbalance of Hsp70 family variants fosters tau accumulation</article-title><source>The FASEB Journal</source><volume>27</volume><fpage>1450</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1096/fj.12-220889</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampinga</surname> <given-names>HH</given-names></name><name><surname>Craig</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The HSP70 chaperone machinery: J proteins as drivers of functional specificity</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>11</volume><fpage>579</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/nrm2941</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamanos</surname> <given-names>TK</given-names></name><name><surname>Tugarinov</surname> <given-names>V</given-names></name><name><surname>Clore</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Unraveling the structure and dynamics of the human DNAJB6b chaperone by NMR reveals insights into Hsp40-mediated proteostasis</article-title><source>PNAS</source><volume>116</volume><fpage>21529</fpage><lpage>21538</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914999116</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname> <given-names>SK</given-names></name><name><surname>Thomas</surname> <given-names>TL</given-names></name><name><surname>Del Tredici</surname> <given-names>K</given-names></name><name><surname>Braak</surname> <given-names>H</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue</article-title><source>Acta Neuropathologica Communications</source><volume>5</volume><elocation-id>41</elocation-id><pub-id pub-id-type="doi">10.1186/s40478-017-0442-8</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname> <given-names>R</given-names></name><name><surname>Tate</surname> <given-names>S-I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impact of the hereditary P301L mutation on the correlated conformational dynamics of human tau protein revealed by the paramagnetic relaxation enhancement NMR experiments</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>3920</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21113920</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kityk</surname> <given-names>R</given-names></name><name><surname>Kopp</surname> <given-names>J</given-names></name><name><surname>Mayer</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular Mechanism of J-Domain-Triggered ATP Hydrolysis by Hsp70 Chaperones</article-title><source>Molecular Cell</source><volume>69</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.12.003</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundel</surname> <given-names>F</given-names></name><name><surname>De</surname> <given-names>S</given-names></name><name><surname>Flagmeier</surname> <given-names>P</given-names></name><name><surname>Horrocks</surname> <given-names>MH</given-names></name><name><surname>Kjaergaard</surname> <given-names>M</given-names></name><name><surname>Shammas</surname> <given-names>SL</given-names></name><name><surname>Jackson</surname> <given-names>SE</given-names></name><name><surname>Dobson</surname> <given-names>CM</given-names></name><name><surname>Klenerman</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Hsp70 inhibits the nucleation and elongation of tau and sequesters tau aggregates with high affinity</article-title><source>ACS Chemical Biology</source><volume>13</volume><fpage>636</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b01039</pub-id><pub-id pub-id-type="pmid">29300447</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundel</surname> <given-names>F</given-names></name><name><surname>Hong</surname> <given-names>L</given-names></name><name><surname>Falcon</surname> <given-names>B</given-names></name><name><surname>McEwan</surname> <given-names>WA</given-names></name><name><surname>Michaels</surname> <given-names>TCT</given-names></name><name><surname>Meisl</surname> <given-names>G</given-names></name><name><surname>Esteras</surname> <given-names>N</given-names></name><name><surname>Abramov</surname> <given-names>AY</given-names></name><name><surname>Knowles</surname> <given-names>TJP</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name><name><surname>Klenerman</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Measurement of tau filament fragmentation provides insights into Prion-like spreading</article-title><source>ACS Chemical Neuroscience</source><volume>9</volume><fpage>1276</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.8b00094</pub-id><pub-id pub-id-type="pmid">29590529</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Qian</surname> <given-names>X</given-names></name><name><surname>Sha</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The crystal structure of the yeast Hsp40 Ydj1 complexed with its peptide substrate</article-title><source>Structure</source><volume>11</volume><fpage>1475</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1016/j.str.2003.10.012</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Fichou</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>Z</given-names></name><name><surname>Hu</surname> <given-names>NY</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Electrostatically driven complex coacervation and amyloid aggregation of tau are independent processes with overlapping conditions</article-title><source>ACS Chemical Neuroscience</source><volume>11</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.9b00627</pub-id><pub-id pub-id-type="pmid">31971365</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandelkow</surname> <given-names>EM</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Biochemistry and cell biology of tau protein in neurofibrillary degeneration</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>2</volume><elocation-id>a006247</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006247</pub-id><pub-id pub-id-type="pmid">22762014</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname> <given-names>JA</given-names></name><name><surname>Singh</surname> <given-names>VK</given-names></name><name><surname>Jia</surname> <given-names>Z</given-names></name><name><surname>Forman-Kay</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Sensitivity of secondary structure propensities to sequence differences between α- and γ-synuclein: Implications for fibrillation</article-title><source>Protein Science</source><volume>15</volume><fpage>2795</fpage><lpage>2804</lpage><pub-id pub-id-type="doi">10.1110/ps.062465306</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisl</surname> <given-names>G</given-names></name><name><surname>Kirkegaard</surname> <given-names>JB</given-names></name><name><surname>Arosio</surname> <given-names>P</given-names></name><name><surname>Michaels</surname> <given-names>TCT</given-names></name><name><surname>Vendruscolo</surname> <given-names>M</given-names></name><name><surname>Dobson</surname> <given-names>CM</given-names></name><name><surname>Linse</surname> <given-names>S</given-names></name><name><surname>Knowles</surname> <given-names>TPJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular mechanisms of protein aggregation from global fitting of kinetic models</article-title><source>Nature Protocols</source><volume>11</volume><fpage>252</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.010</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirbaha</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Morazova</surname> <given-names>OA</given-names></name><name><surname>Ruff</surname> <given-names>KM</given-names></name><name><surname>Sharma</surname> <given-names>AM</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Goodarzi</surname> <given-names>M</given-names></name><name><surname>Pappu</surname> <given-names>RV</given-names></name><name><surname>Colby</surname> <given-names>DW</given-names></name><name><surname>Mirzaei</surname> <given-names>H</given-names></name><name><surname>Joachimiak</surname> <given-names>LA</given-names></name><name><surname>Diamond</surname> <given-names>MI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inert and seed-competent tau monomers suggest structural origins of aggregation</article-title><source>eLife</source><volume>7</volume><elocation-id>e36584</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.36584</pub-id><pub-id pub-id-type="pmid">29988016</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname> <given-names>Y</given-names></name><name><surname>Koren</surname> <given-names>J</given-names></name><name><surname>Kiray</surname> <given-names>J</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies</article-title><source>Future Medicinal Chemistry</source><volume>3</volume><fpage>1523</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.4155/fmc.11.88</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname> <given-names>S-A</given-names></name><name><surname>Condello</surname> <given-names>C</given-names></name><name><surname>Freilich</surname> <given-names>R</given-names></name><name><surname>Gillies</surname> <given-names>A</given-names></name><name><surname>Arhar</surname> <given-names>T</given-names></name><name><surname>Oroz</surname> <given-names>J</given-names></name><name><surname>Kadavath</surname> <given-names>H</given-names></name><name><surname>Julien</surname> <given-names>O</given-names></name><name><surname>Assimon</surname> <given-names>VA</given-names></name><name><surname>Rauch</surname> <given-names>JN</given-names></name><name><surname>Dunyak</surname> <given-names>BM</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Tsai</surname> <given-names>FTF</given-names></name><name><surname>Wilson</surname> <given-names>MR</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping interactions with the chaperone network reveals factors that protect against tau aggregation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0057-1</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname> <given-names>M</given-names></name><name><surname>Knudsen</surname> <given-names>GM</given-names></name><name><surname>Maeda</surname> <given-names>S</given-names></name><name><surname>Trinidad</surname> <given-names>JC</given-names></name><name><surname>Ioanoviciu</surname> <given-names>A</given-names></name><name><surname>Burlingame</surname> <given-names>AL</given-names></name><name><surname>Mucke</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>1183</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1038/nn.4067</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukrasch</surname> <given-names>MD</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>von Bergen</surname> <given-names>M</given-names></name><name><surname>Griesinger</surname> <given-names>C</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sites of tau important for aggregation populate β-Structure and bind to microtubules and polyanions</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>24978</fpage><lpage>24986</lpage><pub-id pub-id-type="doi">10.1074/jbc.M501565200</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukrasch</surname> <given-names>MD</given-names></name><name><surname>von Bergen</surname> <given-names>M</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Fischer</surname> <given-names>D</given-names></name><name><surname>Griesinger</surname> <given-names>C</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The “Jaws” of the Tau-Microtubule Interaction</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>12230</fpage><lpage>12239</lpage><pub-id pub-id-type="doi">10.1074/jbc.M607159200</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukrasch</surname> <given-names>MD</given-names></name><name><surname>Bibow</surname> <given-names>S</given-names></name><name><surname>Korukottu</surname> <given-names>J</given-names></name><name><surname>Jeganathan</surname> <given-names>S</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Griesinger</surname> <given-names>C</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structural polymorphism of 441-Residue tau at single residue resolution</article-title><source>PLOS Biology</source><volume>7</volume><elocation-id>e1000034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000034</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachman</surname> <given-names>E</given-names></name><name><surname>Wentink</surname> <given-names>AS</given-names></name><name><surname>Madiona</surname> <given-names>K</given-names></name><name><surname>Bousset</surname> <given-names>L</given-names></name><name><surname>Katsinelos</surname> <given-names>T</given-names></name><name><surname>Allinson</surname> <given-names>K</given-names></name><name><surname>Kampinga</surname> <given-names>H</given-names></name><name><surname>McEwan</surname> <given-names>WA</given-names></name><name><surname>Jahn</surname> <given-names>TR</given-names></name><name><surname>Melki</surname> <given-names>R</given-names></name><name><surname>Mogk</surname> <given-names>A</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name><name><surname>Nussbaum-Krammer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Disassembly of Tau fibrils by the human Hsp70 disaggregation machinery generates small seeding-competent species</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>9676</fpage><lpage>9690</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013478</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottiger</surname> <given-names>M</given-names></name><name><surname>Delaglio</surname> <given-names>F</given-names></name><name><surname>Bax</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Measurement of J and dipolar couplings from simplified two-dimensional NMR spectra</article-title><source>Journal of Magnetic Resonance</source><volume>131</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1006/jmre.1998.1361</pub-id><pub-id pub-id-type="pmid">9571116</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otting</surname> <given-names>G</given-names></name><name><surname>Rückert</surname> <given-names>M</given-names></name><name><surname>Levitt</surname> <given-names>MH</given-names></name><name><surname>Moshref</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>NMR experiments for the sign determination of homonuclear scalar and residual dipolar couplings</article-title><source>Journal of Biomolecular NMR</source><volume>16</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1023/A:1008372630606</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname> <given-names>KR</given-names></name><name><surname>Ward</surname> <given-names>SM</given-names></name><name><surname>Combs</surname> <given-names>B</given-names></name><name><surname>Voss</surname> <given-names>K</given-names></name><name><surname>Kanaan</surname> <given-names>NM</given-names></name><name><surname>Morfini</surname> <given-names>G</given-names></name><name><surname>Brady</surname> <given-names>ST</given-names></name><name><surname>Gamblin</surname> <given-names>TC</given-names></name><name><surname>Binder</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport</article-title><source>Biochemistry</source><volume>50</volume><fpage>10300</fpage><lpage>10310</lpage><pub-id pub-id-type="doi">10.1021/bi2009147</pub-id><pub-id pub-id-type="pmid">22039833</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname> <given-names>N</given-names></name><name><surname>Sugar</surname> <given-names>J</given-names></name><name><surname>Charya</surname> <given-names>S</given-names></name><name><surname>Johnson</surname> <given-names>G</given-names></name><name><surname>Merril</surname> <given-names>C</given-names></name><name><surname>Bierer</surname> <given-names>L</given-names></name><name><surname>Perl</surname> <given-names>D</given-names></name><name><surname>Haroutunian</surname> <given-names>V</given-names></name><name><surname>Wallace</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease</article-title><source>Molecular Brain Research</source><volume>11</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/0169-328X(91)90033-T</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrucelli</surname> <given-names>L</given-names></name><name><surname>Dickson</surname> <given-names>D</given-names></name><name><surname>Kehoe</surname> <given-names>K</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Snyder</surname> <given-names>H</given-names></name><name><surname>Grover</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation</article-title><source>Human Molecular Genetics</source><volume>13</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh083</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname> <given-names>G</given-names></name><name><surname>Udgaonkar</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Understanding the kinetic roles of the inducer heparin and of Rod-like protofibrils during amyloid fibril formation by tau protein</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>38948</fpage><lpage>38959</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.271874</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renkawek</surname> <given-names>K</given-names></name><name><surname>Bosman</surname> <given-names>G</given-names></name><name><surname>de Jong</surname> <given-names>WW</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia</article-title><source>Acta Neuropathologica</source><volume>87</volume><fpage>511</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1007/BF00294178</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzu</surname> <given-names>P</given-names></name><name><surname>Van Swieten</surname> <given-names>JC</given-names></name><name><surname>Joosse</surname> <given-names>M</given-names></name><name><surname>Hasegawa</surname> <given-names>M</given-names></name><name><surname>Stevens</surname> <given-names>M</given-names></name><name><surname>Tibben</surname> <given-names>A</given-names></name><name><surname>Niermeijer</surname> <given-names>MF</given-names></name><name><surname>Hillebrand</surname> <given-names>M</given-names></name><name><surname>Ravid</surname> <given-names>R</given-names></name><name><surname>Oostra</surname> <given-names>BA</given-names></name><name><surname>Goedert</surname> <given-names>M</given-names></name><name><surname>van Duijn</surname> <given-names>CM</given-names></name><name><surname>Heutink</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the netherlands</article-title><source>The American Journal of Human Genetics</source><volume>64</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1086/302256</pub-id><pub-id pub-id-type="pmid">9973279</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenzweig</surname> <given-names>R</given-names></name><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>Mayer</surname> <given-names>MP</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Hsp70 chaperone network</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>20</volume><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0133-3</pub-id><pub-id pub-id-type="pmid">31253954</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahara</surname> <given-names>N</given-names></name><name><surname>Maeda</surname> <given-names>S</given-names></name><name><surname>Yoshiike</surname> <given-names>Y</given-names></name><name><surname>Mizoroki</surname> <given-names>T</given-names></name><name><surname>Yamashita</surname> <given-names>S</given-names></name><name><surname>Murayama</surname> <given-names>M</given-names></name><name><surname>Park</surname> <given-names>J-M</given-names></name><name><surname>Saito</surname> <given-names>Y</given-names></name><name><surname>Murayama</surname> <given-names>S</given-names></name><name><surname>Takashima</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain</article-title><source>Journal of Neuroscience Research</source><volume>85</volume><fpage>3098</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1002/jnr.21417</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafiei</surname> <given-names>SS</given-names></name><name><surname>Guerrero-Muñoz</surname> <given-names>MJ</given-names></name><name><surname>Castillo-Carranza</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tau oligomers: cytotoxicity, propagation, and mitochondrial damage</article-title><source>Frontiers in Aging Neuroscience</source><volume>9</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2017.00083</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shammas</surname> <given-names>SL</given-names></name><name><surname>Garcia</surname> <given-names>GA</given-names></name><name><surname>Kumar</surname> <given-names>S</given-names></name><name><surname>Kjaergaard</surname> <given-names>M</given-names></name><name><surname>Horrocks</surname> <given-names>MH</given-names></name><name><surname>Shivji</surname> <given-names>N</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Knowles</surname> <given-names>TPJ</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Klenerman</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A mechanistic model of tau amyloid aggregation based on direct observation of oligomers</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7025</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8025</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimura</surname> <given-names>H</given-names></name><name><surname>Miura-Shimura</surname> <given-names>Y</given-names></name><name><surname>Kosik</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>17957</fpage><lpage>17962</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400351200</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storn</surname> <given-names>R</given-names></name><name><surname>Price</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Differential evolution - A simple and efficient heuristic for global optimization over continuous spaces</article-title><source>Journal of Global Optimization</source><volume>11</volume><fpage>341</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1023/A:1008202821328</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tugarinov</surname> <given-names>V</given-names></name><name><surname>Hwang</surname> <given-names>PM</given-names></name><name><surname>Ollerenshaw</surname> <given-names>JE</given-names></name><name><surname>Kay</surname> <given-names>LE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cross-correlated relaxation enhanced 1H[bond]13C NMR spectroscopy of methyl groups in very high molecular weight proteins and protein complexes</article-title><source>Journal of the American Chemical Society</source><volume>125</volume><fpage>10420</fpage><lpage>10428</lpage><pub-id pub-id-type="doi">10.1021/ja030153x</pub-id><pub-id pub-id-type="pmid">12926967</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tugarinov</surname> <given-names>V</given-names></name><name><surname>Kanelis</surname> <given-names>V</given-names></name><name><surname>Kay</surname> <given-names>LE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Isotope labeling strategies for the study of high-molecular-weight proteins by solution NMR spectroscopy</article-title><source>Nature Protocols</source><volume>1</volume><fpage>749</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.101</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Bergen</surname> <given-names>M</given-names></name><name><surname>Friedhoff</surname> <given-names>P</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Heberle</surname> <given-names>J</given-names></name><name><surname>Mandelkow</surname> <given-names>E-M</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure</article-title><source>PNAS</source><volume>97</volume><fpage>5129</fpage><lpage>5134</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.10.5129</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname> <given-names>K</given-names></name><name><surname>Combs</surname> <given-names>B</given-names></name><name><surname>Patterson</surname> <given-names>KR</given-names></name><name><surname>Binder</surname> <given-names>LI</given-names></name><name><surname>Gamblin</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hsp70 alters tau function and aggregation in an isoform specific manner</article-title><source>Biochemistry</source><volume>51</volume><fpage>888</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1021/bi2018078</pub-id><pub-id pub-id-type="pmid">22236337</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vranken</surname> <given-names>WF</given-names></name><name><surname>Boucher</surname> <given-names>W</given-names></name><name><surname>Stevens</surname> <given-names>TJ</given-names></name><name><surname>Fogh</surname> <given-names>RH</given-names></name><name><surname>Pajon</surname> <given-names>A</given-names></name><name><surname>Llinas</surname> <given-names>M</given-names></name><name><surname>Ulrich</surname> <given-names>EL</given-names></name><name><surname>Markley</surname> <given-names>JL</given-names></name><name><surname>Ionides</surname> <given-names>J</given-names></name><name><surname>Laue</surname> <given-names>ED</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The CCPN data model for NMR spectroscopy: Development of a software pipeline</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>59</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1002/prot.20449</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weickert</surname> <given-names>S</given-names></name><name><surname>Wawrzyniuk</surname> <given-names>M</given-names></name><name><surname>John</surname> <given-names>LH</given-names></name><name><surname>Rüdiger</surname> <given-names>SGD</given-names></name><name><surname>Drescher</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The mechanism of Hsp90-induced oligomerizaton of tau</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaax6999</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aax6999</pub-id><pub-id pub-id-type="pmid">32201713</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentink</surname> <given-names>AS</given-names></name><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>Feufel</surname> <given-names>J</given-names></name><name><surname>Ubartaitė</surname> <given-names>G</given-names></name><name><surname>Schneider</surname> <given-names>CP</given-names></name><name><surname>De Los Rios</surname> <given-names>P</given-names></name><name><surname>Hennig</surname> <given-names>J</given-names></name><name><surname>Barducci</surname> <given-names>A</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular dissection of amyloid disaggregation by human HSP70</article-title><source>Nature</source><volume>587</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2904-6</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname> <given-names>D</given-names></name><name><surname>Sykes</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The 13C Chemical-Shift Index: A simple method for the identification of protein secondary structure using 13C chemical-shift data</article-title><source>Journal of Biomolecular NMR</source><volume>4</volume><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1007/BF00175245</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>Q-Q</given-names></name><name><surname>Hong</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Perrett</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct microscopic mechanisms for the accelerated aggregation of pathogenic Tau mutants revealed by kinetic analysis</article-title><source>Physical Chemistry Chemical Physics</source><volume>22</volume><fpage>7241</fpage><lpage>7249</lpage><pub-id pub-id-type="doi">10.1039/C9CP06083A</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69601.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Andreotti</surname><given-names>Amy</given-names></name><role>Reviewing Editor</role><aff><institution>Iowa State University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Kalodimos</surname><given-names>Charalampos Babis</given-names> </name><role>Reviewer</role><aff><institution>St Jude Children's Research Hospital</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.04.11.439324">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.04.11.439324v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper presents a series of elegant biophysical approaches to address the intriguing hypothesis that different molecular chaperones may recognize and bind distinct tau species, and thus may use different mechanisms to prevent tau aggregation. The findings advance our understanding of how chaperones can counteract the deleterious effect of tau amyloidogenesis providing important insights into tau aggregation suppressors that will inform future cell based experiments.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Hsp40s play complementary roles in the prevention of tau amyloid formation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Volker Dötsch as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Charalampos Babis Kalodimos (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) It is proposed that the differential effects resemble either exposure or reduced accessibility of the PHF6 regions. How can DNAJA2 induce NMR spectral changes to the PHF6 region in the non-aggregation-prone tau form, where these regions are proposed to be inaccessible? Does this reflect binding to monomers?</p><p>2) Figure 3 and model fitting: Are the various fittings statistically significant i.e. in Figure 3C an apparent better fitting is found then considering effects on kn and kp, – could this simply reflect allowing an additional parameter/degree of freedom? Moreover, Figure 3-Figure supp 1 is not clear. What is HMWH? Was heparin added? In what concentration? How is that considered when modeling the influence of seeded aggregation? Not knowing how aggregation was induced makes it hard to judge the procedure. It is also not clear what data are plotted in panel A. Is it from panel B or C? The positive curvature of the scaling exponent seems to rely on a single point (the last one). The error bar on this point is compatible with a linear behavior. In addition, I don't see a clear support of the following statement &quot;the scaling exponent was determined to be -0.34 {plus minus} 0.04, which is consistent with a dominant primary nucleation pathway and a contribution stemming from the presence of fibril fragmentation&quot;. It should be described in more details, in particular because it is the base to interpret the fitting of chaperon-inhibited aggregation.</p><p>3) Figure 4: How are the differential effects of heparin and P301S tau species seen upon binding of DNAJB1 and HSPB1 rationalized? The authors suggest that both conditions expose PHF6 motifs, but why are then different interactions observed in the presence of heparin or the P301S mutation? Can the authors provide more information about the structural features of the conformational ensembles in either case? For Figure 4, supplement 1: the authors should show the direct secondary chemical shift differences rather than interpolated SSPs. In any case, there are some differences seen compared to Tau alone and in the presence of heparin, also in the PHF6 regions, that the authors may comment on.</p><p>4) The authors have mainly used NMR line-broadening to report on molecular interactions, which can report on the interfaces proposed but could also involve aggregation of the proteins involved. Can the authors rule out such affects? Also, NMR intensity ratios I/I_0 should indicate error bars, at least for some representative examples.</p><p>5) The authors have used monomeric variants of Hsp40. What are the thoughts on the role of dimeric interactions mediated by the two Hsp40s? How does this affect the proposed interactions and model.</p><p>6) It is difficult to reconcile the results from Figure 3 and from Figure 5 for HSPB1. If HSPB1 inhibits aggregation mostly by slowing elongation, how come the fiber length is unaffected? If it was acting on nucleation, I would expect fewer fibrils of the same length, but if it is acting on elongation, I would expect large numbers of fibrils with smaller length. The explanation given in the results is not convincing to me: &quot;HSPB1 thus appears to only affect the number of fibrils, not the fibril length itself, indicating that its interaction with tau monomers merely slows the fibril elongation rates, but does not prevent their incorporation into the amyloid fibers&quot;.</p><p>7) It seems to be small differences in the interaction regions in tau4RD and 2N4R (Figure 1 supp). From the assignment shown, the region seems to extend up to 318 for 2N4R. This difference would be worth describing and maybe discussing. In the method, it is not mentioned how much assignment was achieved for 2N4R. If this number is low, does it change the confidence in the interaction region of 2N4R?</p><p>8) It is very surprising that addition of the DNAJB1 or DNAJA2 to mature fibrils change so drastically the morphology, seemingly from curly to straight morphology. Could the authors comment on that?</p><p>9) It is mentioned that 88% of non proline residues were assigned. Yet in figure 1D, all residues seem to have an intensity value. It would be more precise not to show an intensity reduction for the residues that could not be assigned.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69601.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) It is proposed that the differential effects resemble either exposure or reduced accessibility of the PHF6 regions. How can DNAJA2 induce NMR spectral changes to the PHF6 region in the non-aggregation-prone tau form, where these regions are proposed to be inaccessible? Does this reflect binding to monomers?</p></disp-quote><p>We thank the reviewers for bringing up this important point. Recent work (by Mirbaha et al., doi: 10.7554/eLife.36584, and Chen at al., doi: 10.1038/s41467-019-10355-1) has shown that inert tau monomers can adopt transient β-hairpin structures that partially shield the aggregation-prone PHF6 motifs. Indeed, our RDC measurements confirm the presence of such a compaction, with large RDCs measured in the PHF6 repeats region (Figure 4 —figure supplement 3). However, even in this more compacted tau state, MD simulation and CS-Rosetta structures of this tau species (Mirbaha et al., doi: 10.7554/eLife.36584) show that the PHF6 hydrophobic side chains are still accessible and available to the chaperones. Thus, we hypothesize that HspB1 chaperone and DNAJA2 (via its CTDI domain), which are known to interact with the hydrophobic side chains in peptides, can bind to this monomeric tau state.</p><p>Interestingly, we find that the CTDII sites of both DNAJB1 and DNAJA2 chaperones do not recognize this compact monomeric tau state, but can rather bind with high affinity to the extended tau conformation. While further studies (outside the scope of this manuscript) will be required to fully understand the structural preferences in the CTDII domains of DNAJA2 and DNAJB1, there are several possible options – (1) the binding to CTDII domains involves backbone residues that only become exposed in the expanded tau conformation, or (2) the PHF6 domains need to interact simultaneously with the two CTDII domains in the DNAJA2 and DNAJB1 dimers, which can only take place in the expanded PHF6 conformation, or rather (3) additional residues required for the binding only become accessible in the aggregation-prone expanded tau conformation.</p><disp-quote content-type="editor-comment"><p>2) Figure 3 and model fitting: Are the various fittings statistically significant i.e. in Figure 3C an apparent better fitting is found then considering effects on kn and kp, – could this simply reflect allowing an additional parameter/degree of freedom?</p></disp-quote><p>This is indeed a very important point and we thank the reviewers for bringing it up. To validate that the DNAJA2 chaperone indeed affects several rates with higher accuracy, we have recorded an additional set of kinetic experiments measuring the aggregation prevention by DNAJA2 chaperones on seeded tau aggregation. The idea behind these seeded experiments is that under seeding conditions, the primary nucleation events are negligible, allowing us to obtain a better precision in determining the effect of the chaperone on other rates such as elongation. We therefore globally fit this substantially increased data set of seeded and unseeded experiments in the presence of DNAJA2 chaperone with three degrees of freedom (nucleation rates, elongation rates, and fragmentation rates).</p><p>The results from the new experiments (shown in revised manuscript figure 3 —figure supplement 2) show with statistical significance that DNAJA2 chaperone indeed reduces the rates of tau elongation and nucleation.</p><disp-quote content-type="editor-comment"><p>Moreover, Figure 3-Figure supp 1 is not clear. What is HMWH? Was heparin added? In what concentration? How is that considered when modeling the influence of seeded aggregation? Not knowing how aggregation was induced makes it hard to judge the procedure. It is also not clear what data are plotted in panel A. Is it from panel B or C?</p></disp-quote><p>Following the reviewers’ comments regarding the legend of Figure 3-Figure supp 1, the term HMWH, which referred to high molecular weight heparin, has been corrected to heparin. The legend now also includes the concentrations of heparin used (0.5:1 molar ratio heparin to monomeric tau in all the unseeded reactions).</p><p>We have likewise added a detailed description to the methods section of the procedure used for fitting the aggregation kinetics, both for the seeded and unseeded tau.</p><disp-quote content-type="editor-comment"><p>The positive curvature of the scaling exponent seems to rely on a single point (the last one). The error bar on this point is compatible with a linear behavior. In addition, I don't see a clear support of the following statement &quot;the scaling exponent was determined to be -0.34 {plus minus} 0.04, which is consistent with a dominant primary nucleation pathway and a contribution stemming from the presence of fibril fragmentation&quot;. It should be described in more details, in particular because it is the base to interpret the fitting of chaperon-inhibited aggregation.</p></disp-quote><p>We agree with the reviewer on this and have therefore added an additional measurement point of 40 μm monomeric tau to the plot, which better shows the appearance of the positive curvature. It is, however, important to note that the mechanism of tau aggregation has been previously reported to consist of the saturating elongation step (which is indicated by the positive curvature in the double logarithmic plots), and our current results only serve to confirm that this is also the case under our experimental conditions.</p><p>As for the scaling exponent, this was calculated from the half-times of tau aggregation at various concentrations, and the tau aggregation mechanism was determined based on the procedure published by Tuomas Knowles’ group in Nature protocols (https://doi.org/10.1038/nprot.2016.010). The reported scaling factor corresponds to the initial, linear part of the curve, excluding the points showing the positive curvature. We have added a detailed explanation of the procedure both in the main text and in the figure legend of Figure 3 – figure 1 supplement 1 of the revised manuscript:</p><p>“To extract the scaling factor (γ), the half-times (t1/2) of the aggregation reaction were plotted versus the tau monomer concentration on a double logarithmic plot with the slope of this plot providing the scaling exponent (log(t1/2) = γlog(m0) + constant). By using the rate laws for the time evolution of aggregate mass, γ can be related to the reaction orders for each of the models. The scaling factor for tau aggregation was calculated to be -0.34±0.04, with -0.5&lt;γ&lt;0 indicating primary nucleation and fragmentation as the correct model. Furthermore, the deviation of the points from a straight line shows that γ is dependent on the monomer concentration, with positive curvature indicating the presence of saturating elongation (45).”</p><disp-quote content-type="editor-comment"><p>3) Figure 4: How are the differential effects of heparin and P301S tau species seen upon binding of DNAJB1 and HSPB1 rationalized? The authors suggest that both conditions expose PHF6 motifs, but why are then different interactions observed in the presence of heparin or the P301S mutation? Can the authors provide more information about the structural features of the conformational ensembles in either case?</p></disp-quote><p>While both heparin binding and the P301S mutation result in the increase of the “aggregation-prone” conformation of tau, with the more expanded PHF6 motifs, the two species differ dramatically in their populations of this conformation. In the case of heparin-bound tau, the aggregation-prone, expanded species is the major, highly-populated state of the protein, while the P301S/L mutations merely cause an increase in the population of the expanded conformers within the structural ensemble (as reported by Chen at al., doi: 10.1038/s41467-019-10355-1 and Kawasaki and Tale doi.org/10.3390/ijms21113920). Based on previous publications and our RDC measurements, in the mutants this expanded species represents just a small percentage (~15%) of the overall ensemble, and therefore only interacts with DNAJB1 weakly (although significantly better than the WT tau). The remaining ~90%, however (the inert tau population), can still readily bind to HSPB1.</p><disp-quote content-type="editor-comment"><p>For Figure 4, supplement 1: the authors should show the direct secondary chemical shift differences rather than interpolated SSPs. In any case, there are some differences seen compared to Tau alone and in the presence of heparin, also in the PHF6 regions, that the authors may comment on.</p></disp-quote><p>We have added a secondary chemical shifts plot to Figure 4 —figure supplement 1 (panel D), which does not show any significant changes in the secondary structure propensities between tau and heparin-bound tau species.</p><disp-quote content-type="editor-comment"><p>4) The authors have mainly used NMR line-broadening to report on molecular interactions, which can report on the interfaces proposed but could also involve aggregation of the proteins involved. Can the authors rule out such affects?</p></disp-quote><p>In order to rule out the presence of aggregation, we ran a set of DLS experiments conducted at identical protein concentrations and conditions as our NMR binding experiments. We did not observe any changes in particle size for tau-chaperone complexes over the course of 4 hours, indicating that these do not aggregate in the course of our NMR measurements. Furthermore, DLS measurements of tau and tau-heparin samples also showed that these proteins remain stable during our measurements and do not aggregate.</p><disp-quote content-type="editor-comment"><p>Also, NMR intensity ratios I/I_0 should indicate error bars, at least for some representative examples.</p></disp-quote><p>We have calculated the error bars for all tau-chaperone NMR binding experiments. These are added as source data for figures 1 and 4 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) The authors have used monomeric variants of Hsp40. What are the thoughts on the role of dimeric interactions mediated by the two Hsp40s? How does this affect the proposed interactions and model.</p></disp-quote><p>We thank the reviewers for bringing up this interesting point. We now make it more clear in the manuscript that in all biochemical experiments and NMR experiments with 15N-labeled tau we used the full length versions of the chaperones. Also all the affinities reported in the paper were likewise acquired with these full length, dimeric versions of the proteins. The truncated variant was used only when characterizing the interaction of tau with labeled DNAJA2 chaperone (i.e., from the chaperone side), where a monomeric version of DNAJA2 yeast homologue Ydj1 was used.</p><p>We have added an explicit explanation to the text of the revised manuscript regarding the truncated construct used.</p><p>Furthermore, in order to ensure that the interaction of the aggregation-prone tau, which we mapped to the CTDII region of Ydj1, was not affected by the lack of the dimerization domain and C-terminal tail of the chaperone, we have repeated the binding experiments using the dimeric form of the DNAJA2 CTDII domains (CTDII+DD construct – residues 256-409). The construct showed significant chemical shift perturbation upon binding to tau-heparin, but not to tau alone, confirming that the aggregation-prone species indeed interacts with DNAJA2 CTDII.</p><disp-quote content-type="editor-comment"><p>6) It is difficult to reconcile the results from Figure 3 and from Figure 5 for HSPB1. If HSPB1 inhibits aggregation mostly by slowing elongation, how come the fiber length is unaffected? If it was acting on nucleation, I would expect fewer fibrils of the same length, but if it is acting on elongation, I would expect large numbers of fibrils with smaller length. The explanation given in the results is not convincing to me: &quot;HSPB1 thus appears to only affect the number of fibrils, not the fibril length itself, indicating that its interaction with tau monomers merely slows the fibril elongation rates, but does not prevent their incorporation into the amyloid fibers&quot;.</p></disp-quote><p>We thank the reviewers for this comment, which brought to our attention the inadequate explanation of the results observed in figure 5 in our original manuscript.</p><p>Reanalyzing of EM images showed that the addition of HSPB1 chaperone to the aggregation reaction does result in a minor decrease of fibril length, however one that is significantly smaller to what was observed in the presence of the J-domain proteins. This small reduction is also consistent with our aggregation kinetics measurements, which showed only a small (16%) reduction of fibril mass upon addition of HSPB1 chaperone at 0.25:1 HSPB1:tau ratio. However, since fibril mass decrease can result from either reduction in fibril length or from an overall decrease of the number of fibrils, this can only serve as an upper bound for the reduction in fibril length. Regardless, such small changes in length are difficult to accurately quantify from the EM images, leading to our assumption that HSPB1 does not result in changes to fibril length. Even the addition of 0.75:1 ratio of HSPB1:tau only decreased fibril mass by 37%, which is significantly smaller effect than that of the DNAJA2 and DNAJB1 chaperones, which reduced fibril mass by 91% and 87%, respectively. Due to these diminished reductions, identifying the specific effects of HSPB1 on fibril length would require analysis outside the scope of this manuscript.</p><p>Overall, HSPB1 chaperone only has a minor effect on slowing down fiber formation, which is a result of both the weak interaction of the chaperone solely with the monomeric tau species, and its limited ability to reduce the rate of tau elongation into the growing fibers.</p><p>New plots, showing the decrease in fibril mass as a function of chaperone concentration are now included as Figure 5 —figure supplement 1 in the revised manuscript. Furthermore, the section describing the “Changes to tau fibers caused by the chaperones” has been rewritten to incorporate the points discussed above:</p><p>“Since ThT fluorescence only reports on total fibril mass, with no differentiation to fibril length or number, we turned to EM in order to image the fibers. […] Thus, the weak interaction of HSPB1 with tau monomers along with its limited ability to only slow down the fibril elongation rates, is not sufficient to efficiently prevent tau incorporation into the amyloid fibers.”</p><disp-quote content-type="editor-comment"><p>7) It seems to be small differences in the interaction regions in tau4RD and 2N4R (Figure 1 supp). From the assignment shown, the region seems to extend up to 318 for 2N4R. This difference would be worth describing and maybe discussing. In the method, it is not mentioned how much assignment was achieved for 2N4R. If this number is low, does it change the confidence in the interaction region of 2N4R?</p></disp-quote><p>Indeed, when adding HSPB1 to tau 2N4R, the peak broadening extends also to residues 314-318. This broadening of the extra 4 residues could possibly be attributed to the larger size, and therefore slower tumbling times, of the full length tau compared to tau 4RD.</p><p>It is important to note, however, that all the residues in tau 2N4R that show peak broadening upon binding to HSPB1 and DNAJA2 have been assigned and were found to be located in the PHF6 regions.</p><disp-quote content-type="editor-comment"><p>8) It is very surprising that addition of the DNAJB1 or DNAJA2 to mature fibrils change so drastically the morphology, seemingly from curly to straight morphology. Could the authors comment on that?</p></disp-quote><p>We were also very intrigued by this drastic change in fiber appearance. After re-reading the manuscript, though, we think that the term “morphology” may be a bit misleading. We cannot determine whether the addition of the chaperones indeed modifies the fiber morphology, or whether this is just due to the fiber mobility being restricted as a result of the chaperones binding densely on the fiber, thereby changing their appearance to less twisted, straighter fibers. We have therefore changed the term “morphology” to “appearance” in the revised version of the manuscript</p><disp-quote content-type="editor-comment"><p>9) It is mentioned that 88% of non proline residues were assigned. Yet in figure 1D, all residues seem to have an intensity value. It would be more precise not to show an intensity reduction for the residues that could not be assigned.</p></disp-quote><p>The unassigned residues were never included in our intensity plots, but rather the numbering was non-continuous in our figures. We have now included plots, along with a full table of intensities, that specifically indicate the unassigned residues for all tau-chaperone NMR binding experiments.</p><p>These have been added as source data for figures 1 and 4 in the revised manuscript.</p></body></sub-article></article>